



2-4 April 2020

Vienna, Austria

World Congress of Brachytherapy

Scientific
Programme

**Thursday
2 April
2020**



World Congress of Brachytherapy

Plenary Session: Welcome and introduction

08:00 - 08:15

Room C8

08:00 Welcome and introduction

Chair: B. Pieters (The Netherlands)

World Congress of Brachytherapy

Teaching Lecture: Transrectal ultrasound for gynaecological cancer brachytherapy

08:15 - 08:55

Room C8

Chair: L. Beaulieu (Canada)

- 08:15 **Transrectal ultrasound for gynaecological cancer brachytherapy** SP-001
M. Schmid (Austria)

World Congress of Brachytherapy

Debate: This house believes that combination therapy for intermediate and high-risk prostate cancer represents best standard of care

09:00 - 10:15

Room C8

Chair: Y. Yoshioka (Japan)

Co-chair: P. Hoskin (United Kingdom)

- 09:00 **For the motion** SP-002
M. Keyes (Canada)
- 09:20 **Against the motion: Data, data, data** SP-003
D. Spratt (USA)

09:40	For the motion rebuttal <u>A. Gomez-Iturriaga</u> (Spain)	SP-004
09:50	Brachytherapy Boost for Prostate Cancer - A Diminishing Solution <u>J. Martin</u> (Australia)	SP-005

World Congress of Brachytherapy

Symposium: Brachytherapy physics 2030 – Dosimetry for nuclides and radiation

09:00 - 10:15

Room C7

Source strength standardization and dosimetry accuracy are essential for proper brachytherapy dose delivery and clinical trial consistency. This symposium will highlight the latest advances in nuclide dosimetry, clinical calibrations, and brachytherapy treatment planning calculations. The first lecture will feature recent projects in metrology and the ongoing development of a calibration service. The second lecture will review HDR and LDR calibration methods at the clinical level. The timing, resource requirements, tolerance actions, and application of clinical calibrations will be discussed. The final lecture will examine calculations methods that incorporate heterogeneities including model-based systems, artificial intelligence solutions, IMBT, and multiscale dose calculations.

Chair: C. Kirisits (Austria)

Co-chair: C. Deufel (USA)

09:00	Nuclides and dose delivery devices – An overview and Comparison <u>D. Baltas</u> (Germany)	SP-006
09:18	Traceability of LDR and HDR source calibration <u>T. Schneider</u> (Germany)	SP-007
09:36	Calibration at the clinical level for HDR and LDR brachytherapy sources <u>M. Rivard</u> (USA)	SP-008
09:54	Dosimetry beyond TG43 - Radiobiological models combined with model based and deep convolutional neural network algorithms <u>S. Enger</u> (Canada)	SP-009

World Congress of Brachytherapy

Proffered Papers: Proffered papers 1 - Partial Breast

10:45 - 11:45

Room C8

Chair: *TBC*

Co-chair: K. Lössl (Switzerland)

- 10:45 **APBI vs. very APBI in the elderly: a comparison analysis of oncological outcome and late toxicity** OC-010
J. Hannoun-Levi, L.C.K. Daniel, G. Jocelyn, S. Renaud, G. Mathieu, C. Marie-Eve (France)
- 10:55 **Very Accelerated Partial Breast Irradiation (VAPBI)..HDR brachytherapy phase I-II multicenter trial** OC-011
J. Guinot, V. Gonzalez-Perez, N. Meszaros, T. Major, C. Polgar, D. Najjari, C. Gutierrez-Miguelez, M.A. Santos (Spain)
- 11:05 **APBI using multi-catheter interstitial HDR brachytherapy: A 15-year update of a prospective registry** OC-012
P. Gabani, W. Kennedy, M. Thomas, J. Zoberi, L. Ochoa, M. Matesa, I. Zoberi (USA)
- 11:15 **Comparison of Guidelines for Early Stage Breast Cancer Patients Treated with APBI Brachytherapy** OC-013
M. Mills, R. Nanda, J. Wilson, T. Altoos, D. Caldwell, L. Stout, S. Dube, K. Allen, P. Blumencranz, R. Diaz (USA)
- 11:25 **Phase I/II trial of ultra-APBI on early breast cancer (4f-APBI): Initial feasibility results.** OC-014
M. Gimeno Morales, R. Martínez-Monge, F. Martínez-Regeira, N. Rodríguez-Spiteri, B. Olartecoechea, L. Ramos, L. Pina, A. Elizalde, M. Idoate, M. Abengozar, J. Aristu, M. Moreno, L. Arbea, J.M. Aramendía, M. Santisteban, P. Jablonska, A. García-Consuegra, S. Fardique, M. Cambeiro (Spain)
- 11:35 **APBI is associated with equivalent cosmesis to whole breast external beam radiotherapy** OC-015
L. Moses, P. Graham, A. Bece, Y. Chin (Australia)

World Congress of Brachytherapy

Proffered Papers: Proffered papers 2 - Rectum & Skin

10:45 - 11:45

Room C7

Chair: T. Vuong (Canada)

Co-chair: D. Wood (Australia)

- | | | |
|-------|--|--------|
| 10:45 | Outcomes of CT-guided radioactive 125I seed implantation for locally recurrent rectal cancer | OC-016 |
| | <u>L. Wang</u> , H. Wang, Y. Jiang, Z. Ji, F. Guo, P. Jiang, X. Li, Y. Chen, H. Sun, J. Fan, G. Du, J. Wang (China) | |
| 10:55 | MAASTRO applicator, a novel rectal applicator for contact brachytherapy with 192Ir HDR sources | OC-017 |
| | <u>M. Bellezzo</u> , G.P. Fonseca, R. Voncken, A. Verrijssen, C. Van Beveren, E. Roelofs, H. Yoriyaz, B. Reniers, E.J. Van Limbergen, M. Barbée, F. Verhaegen (The Netherlands) | |
| 11:05 | Interstitial brachytherapy in non-melanoma skin cancer. Results of an expert center. | OC-018 |
| | <u>G. Antelo-redondo</u> , J. Gonzalez Vigueras, I. Visus Fernández de Manzanos, D. Najjari Jamal, A. Slocker Escarpa, H. Pérez Montero, I. Linares Galiano, R. Gracia Lucio, F. Guedea Edo, C. Gutiérrez Miguélez (Spain) | |
| 11:15 | Superficial HDR brachytherapy for skin lesions involving the finger – The Christie experience. | OC-019 |
| | <u>A. Rembielak</u> , J.D. Bedford, S. Wilson (United Kingdom) | |
| 11:25 | Adjuvant superficial 2D HDR brachytherapy for skin BCC after surgical resection. | OC-020 |
| | <u>A. Chyrek</u> , W. Burchardt, G. Bielęda, A. Chicheł (Poland) | |
| 11:35 | Promising Outcomes of Perioperative Interstitial HDR Brachytherapy in adjuvant treatment of keloids | OC-021 |
| | <u>A. George</u> , K. Koushik, R. C. Alva (India) | |

World Congress of Brachytherapy

Poster discussion: Poster discussion 1

10:45 - 11:45

Brachy Village: Poster Discussion Station

Chair: Å. Carlsson Tedgren (Sweden)

Co-chair: R. Bhalavat (India)

10:45	Eye HDR brachytherapy using Yb-169 <u>J. Dupere</u> , J. J Munro III, D. C Medich (USA)	PD-022
10:50	Results of 125I Seed Implantation for Recurrent Carcinoma of Head and Neck Assisted by 3D Plate <u>Y. Jiang</u> (China)	PD-023
10:55	Real-time electromagnetic guidance for GYN interstitial HDR brachytherapy: a proof-of-concept <u>A. Cantin</u> , M. Lavallée, E. Poulin, W. Foster, L. Beaulieu (Canada)	PD-024
11:00	Assessment of interstitial needles with 3D-TRUS in cervical cancer brachytherapy <u>J. Knoth</u> , N. Nesvacil, A. Sturdza, G. Kronreif, J. Widder, C. Kirisits, M. Schmid (Austria)	PD-025
11:05	Implant-based CT estimation towards adaptive breast brachytherapy M. Schulz, K. Kallis, T. Geimer, N. Abu-Hossin, <u>C. Dürrbeck</u> , V. Strnad, A. Maier, R. Fietkau, C. Bert (Germany)	PD-026
11:10	Long term outcomes of Carcinoma Buccal Mucosa treated with High Dose Rate Interstitial Brachytherapy <u>H.K. Bajwa</u> , R. Singareddy, K.R. Alluri (India)	PD-027
11:15	A Miniature Robotic System For Interstitial Brachytherapy Needle Insertion <u>I. Buzurovic</u> , H. Pei, Y. Hu (Usa)	PD-028
11:20	Multi-Criteria Optimization Integrating Catheter Number And Position For Prostate Hdr Brachytherapy <u>P. Chatigny</u> , C. Bélanger, É. Poulin, L. Beaulieu (Canada)	PD-029

11:25	Characterisation of an inorganic scintillation detector system for time resolved <i>in vivo</i> dosimetry	PD-030
	<u>J. Johansen</u> , E.B. Jørgensen, D. Piché-Meunier, H.M.L. Rosales, D. Tho, K. Tanderup, S. Beddar, L. Beaulieu, G. Kertzscher (Denmark)	
11:30	Establishing a Fingerprinting Method for Fast Catheter Identification in HDR Brachytherapy	PD-031
	<u>D. Tho</u> , E. B. Jørgensen, H. M L Rosales, C. Bélanger, J. G. Johansen, G. Kertzscher, L. Beaulieu (Canada)	
11:35	Influence of tumor shape and location in eye plaque brachytherapy dosimetry	PD-032
	<u>M. Studenski</u> , N.V. Patel, A. Markoe, J.W. Harbour, S.E. Samuels (USA)	
11:40	Introducing a new HDR system into an existing HDR Brachytherapy clinic using TG100 methodology	PD-033
	<u>E. Sullivan</u> , E. Flower, G. Busutil, S. Zanjani, K. Tran, H. Nguyen, V. Nguyen, J. Beech, D. Thwaites, J. Sykes, J. Chard, A. Salkeld (Australia)	

World Congress of Brachytherapy

Proffered Papers: 3 Best Moderated Abstracts

11:45 - 12:45		Room C8
	Chair: D. Petereit (USA)	
	Co-chair: S. Chopra (India)	
11:45	Local failure in cervical cancer patients after MR image-guided adaptive brachytherapy	OC-034
	<u>M. Schmid</u> , C. Kirisits, K. Tanderup, C. Haie-Meder, L. Fokdal, A. Sturdza, P. Hoskin, U. Mahantshetty, B. Segedin, K. Bruheim, F. Huang, B. Rai, R. Cooper, E. Van der Steen-Banasik, E. Van Limbergen, B. Pieters, L.T. Tan, R. Nout, A.A.C. De Leeuw, N. Nesvacil, I. Jürgenliemk-Schulz, J.C. Lindegaard, R. Pötter, E. Collaborative Group (Austria)	
12:00	Moderator: A. Viswanathan (USA)	
12:05	Partial Or Whole Breast Irradiation After BCS: 20-Year Results Of A Randomized Clinical Trial	OC-035
	<u>C. Polgár</u> , T. Major, Z. Takacs-Nagy, J. Fodor (Hungary)	
12:20	Moderator: tbc	

- 12:25 **Intensity Modulated Ir-192 Brachytherapy Using 3D Printed Shielded Applicators** OC-036
L. Skinner, T. Niedermayr, J. Perl, N. Prionas, F. Benjamin, E. Kidd (USA)
- 12:40 Moderator: A. De Leeuw (The Netherlands)

World Congress of Brachytherapy

Symposium: Image guided BT and Outcome for Cervical Cancer: Update from different regions

14:15 - 15:30 Room C8

- Chair: I. Jürgenliemk-Schulz (The Netherlands)
Co-chair: U. Mahantshetty (India)
- 14:15 **EMBRACE experience** SP-037
R. Pötter, O.B.O.T.E.S.A.R.G. On Behalf Of The Embrace Study And Research Group (Austria)
- 14:33 **Image guided Brachytherapy and Outcomes of Cervical Cancer:: Indian Experience** SP-038
N. Lavanya (India)
- 14:51 **Cervical Cancer Brachytherapy at Washington University:1920-2020** SP-039
P. Grigsby (USA)
- 15:09 **Transition from 2D to MRI-based adaptive brachytherapy, Chulalongkorn University experience.** SP-040
N. Amornwichet, C. Khorprasert, P. Alisanant, K. Shotelersuk (Thailand)

World Congress of Brachytherapy

Symposium: Eye/orbital brachytherapy: from organ sparing to function sparing

14:15 - 15:30

Room C7

Chair: L. Tagliaferri (Italy)

Co-chair: A. Chichel (Poland)

- | | | |
|-------|--|--------|
| 14:15 | Choice of the best approach for eye melanoma
<u>V. Cohen</u> (United Kingdom) | SP-041 |
| 14:40 | The role of interstitial radiotherapy in orbital tumors or extrascleral uveal melanoma
<u>G. Kovács, Prof. Dr. Dr.</u> (Germany) | SP-042 |
| 15:05 | Brachytherapy toxicity: diagnosis, therapies and preventive strategies
<u>M.A. Blasi</u> (Italy) | SP-043 |

World Congress of Brachytherapy

Proffered Papers: Proffered papers 3 - Prostate outcome

16:00 - 17:00

Room C8

Chair: B. Prestidge (USA)

Co-chair: C. Salembier (Belgium)

- | | | |
|-------|---|--------|
| 16:00 | Patterns of recurrence and associated factors after prostate permanent brachytherapy
<u>A. Yorozu, T. Soyano, S. Sutani, Y. Shiraishi, S. Saito, K. Nakamura, T. Nishiyama, Y. Yagi, K. Toya</u> (Japan) | OC-044 |
| 16:10 | HDR brachytherapy vs stereotactic boost in treatment of prostate cancer: comparison of safety profile
<u>S. Novikov, M. Gotovchikova, N. Ilin, R. Novikov, Y. Merezhko, J. Melnik, S. Kanaev</u> (Russian Federation) | OC-045 |

16:20	Dose Escalation Versus Androgen Suppression In Locally Advanced Prostate Cancer. 10 Year Outcomes	OC-046
	<u>D. Joseph</u> , J. Denham, A. Steigler, D. Lamb, N. Spry, J. Stanley, T. Shannon, G. Duchesne, C. Atkinson, J. Matthews, S. Turner, L. Kenny, D. Christie, K. Tai, N.K. Gogna, R. Kearvell, J. Murray, M. Ebert, A. Haworth, B. Delahunt, C. Oldmeadow, J. Attia (Australia)	
16:30	Toxicity and clinical outcomes of LDR versus HDR brachytherapy boost: propensity-score analysis	OC-047
	<u>A. Goni Ramirez</u> , A. Gomez-Iturriaga Piña, M.B. De Paula Carranza, E.M. Saenz de Urturi Albisu, M. Egiguren Bastida, M. Pagola Divasson, I. Gutierrez Betondo, N. Bultó Boque, D.I. Ortiz de Urbina Ugarte, V. Pastor Sanchis, A. Bartrés Salido, M. Erzilbengoa, J. Rosa Nieto (Spain)	
16:40	Comparing GU toxicity of LDR I-125 prostate brachytherapy by robotic and manual loading techniques	OC-048
	<u>P. McLaughlin</u> , P.L. Nguyen, I. Buzurovic, D. Cail, J. Adleman, P.F. Orio III, M.T. King (Canada)	
16:50	Validation of the bladder neck as a significant OAR at prostate seed brachytherapy based on D2cc	OC-049
	<u>N. Wallace</u> , M.F. Jamaluddin, P.J. Kelly (Ireland)	

World Congress of Brachytherapy

Proffered Papers: Proffered papers 4 - Nuclides and treatment planning

16:00 - 17:00 Room C7

Chair: F. Siebert (Germany)

Co-chair: M. Rivard (USA)

16:00	Expanding Calibration Service for LDR Brachytherapy Seeds by Photon Fluence Determination	OC-050
	<u>T. Schneider</u> , A. Kasper, G. Winterbottom (Germany)	

- 16:10 **Brachytherapy TG-43 dosimetry characterization of the INTRABEAM source** OC-051
D.S. Ayala Alvarez, P.G.F. Watson, M. Popovic, J. Seuntjens (Canada)
- 16:20 **Comparison of TG43 and TG186 dose calculations for 100 patients receiving breast brachytherapy** OC-052
A. Howie, J. Poder, R. Brown, K. Schreiber, A. Bece, P. Graham, Y. Chin (Australia)
- 16:30 **Experimental validation of 169Yb source dosimetry using multipoint plastic scintillator detector** OC-053
G. Famulari, H.M. Linares Rosales, J. Dupere, D.C. Medich, L. Beaulieu, S.A. Enger (Canada)
- 16:40 **Deep-learning based Physician's Preference Prediction for HDR Brachytherapy of Cervical Cancer** OC-054
Y. Gonzalez, C. Shen, C. Wang, K. Albuquerque, X. Jia (USA)
- 16:50 **Automated multi-criteria treatment planning for adaptive HDR-BT for locally advanced cervical cancer** OC-055
M. Oud (awardee), I. Kolkman-Deurloo, J. Mens, D. Lathouwers, Z. Perkó, B. Heijmen, S. Breedveld (The Netherlands)

**Friday
3 April
2020**



World Congress of Brachytherapy

Teaching Lecture: Using health economics to make the case for brachytherapy – HALYS, QALYS and DALYS

08:00 - 08:40

Room C8

Chair: P. Orio (USA)

- | | | |
|-------|---|--------|
| 08:00 | Using health economics to make the case for brachytherapy – HALYS, QALYS and DALYS
<u>M. Milosevic</u> (Canada) | SP-056 |
| 08:00 | Using health economics to make the case for brachytherapy – HALYS, QALYS and DALYS
<u>D. Rodin</u> (Canada) | SP-057 |

World Congress of Brachytherapy

Debate: Partial Breast Irradiation with 1-3 fractions

08:45 - 10:00

Room C8

Four international experts will discuss current results of very accelerated partial breast irradiation (VAPBI) trials using only 1 – 3 fractions in 1-2 days and corresponding perspectives.

Jean-Michel Hannoun-Levi and Robert Kuske will report the entry criteria, techniques and results of VAPBI trials and comparison with contemporary results of Phase 3 APBI-trials. The similarities, differences and challenges will be critical discussed.

Philip Poortmans and Icro Meattini will present critical overview of primary and secondary outcomes of main phase 3 trials using different approaches for APBI. Finally, the cost effectiveness of the different approaches for partial breast irradiation will be evaluated.

Chair: V. Strnad (Germany)

Co-chair: C. Yashar (USA)

- | | | |
|-------|--|--------|
| 08:45 | For the motion
<u>J. Hannoun-Levi</u> (France) | SP-058 |
| 09:05 | Against the Motion
<u>P. Poortmans</u> , I. Meattini (Belgium) | SP-059 |

09:25	For the Motion Rebuttal	SP-060
	R. Kuske (Usa)	
09:35	Against the Motion Rebuttal	SP-061
	<u>I. Meattini</u> , P. Poortmans (Italy)	
09:45	Discussion	

World Congress of Brachytherapy

Symposium: Brachytherapy physics 2030 – Enhanced application and in-vivo treatment verification

08:45 - 10:00

Room C7

The use of complex techniques and in-vivo treatment verification in brachytherapy is expanding. In this symposium, the current status of customized applicator, and treatment plan creation will first be reviewed. Then electromagnetic tracking technology, its limitations and potential benefits, and current clinical use will be discussed. After this, the benefits, current practical challenges, and clinical applications of in-vivo source tracking with point dosimeters will be reviewed. The session will conclude with an overview of in-vivo source tracking with imaging panels and fluoroscopy, a discussion of published literature, results from phantom studies, and the current state of the technology.

	Chair: K. Tanderup (Denmark)	
	Co-chair: K. Martell (Canada)	
08:45	Increasing the degrees of freedom with applicators	SP-062
	<u>A. Damato</u> (USA)	
09:03	Electromagnetic tracking in brachytherapy	SP-063
	<u>A. Ravi</u> (Canada)	
09:21	In vivo HDR brachytherapy source tracking with point dosimeters: current status and future directions	SP-064
	<u>J. Poder</u> , D. Cutajar, M. Carrara, S. Guatelli, M. Petasecca, M. Lerch, A. Howie, J. Bucci, A. Rosenfeld (Australia)	

09:39	In vivo source tracking with imaging panels and fluoroscopy <u>G. Fonseca</u> , C. Van Beveren, R. Voncken, M. Bellezzo, F. Verhaegen (The Netherlands)	SP-065
-------	---	--------

World Congress of Brachytherapy

Proffered Papers: Proffered papers 5 - Optimising outcome in cervix BT

10:30 - 11:30	Room C8
---------------	---------

	Chair: N. Amornwichet (Thailand) Co-chair: P. Petric (Slovenia)	
10:30	Dose to vaginal wall in cervical cancer brachytherapy and associated morbidity <u>M. Serban</u> , A.A.C. De Leeuw, K. Tanderup, I.M. Jürgenliemk-Schulz (Denmark)	OC-066
10:40	Dose-effect relationship between vaginal dose points and vaginal stenosis in cervical cancer <u>H. Westerveld</u> , K. Kirchheimer, R.A. Nout, K. Tanderup, J.C. Lindegaard, S. Spampinato, A. Sturdza, N. Nesvacil, K. Bruheim, T.P. Hellebust, B.R. Pieters, I.M. Jürgenliemk-Schulz, R. Pötter, A. De Leeuw (The Netherlands)	OC-067
10:50	Improving needle placement and efficiency with real-time 1.5T MR-tracking of interstitial implants <u>M. Morcos</u> , J. Lee, E.J. Schmidt, A.N. Viswanathan (USA)	OC-068
11:00	Optimizing Real-Time MRI-Guided Interstitial Brachytherapy Application for Gynecologic Cancer <u>J. Adleman</u> , R. Cormack, G. Alban, I. Buzurovic, T. Cheng, T. Harris, M. King, J. Tokuda, L. Lee (USA)	OC-069

11:10	Dosimetric outcome of single application multi-fractionated HDR Brachytherapy for cervical cancer <u>S. Bushra</u> , U. Mahantshetty, L. Gurram, A. Pilar, S. Chopra, Y. Ghadi, D. Aravind, R. Mhatre, U. Upreti, J. Swamidas (India)	OC-070
11:20	Use of Ultrasound-Compatible Models for Simulation-Based Gynecological Education <u>L. Singer</u> , S. Damast, J. Chino, N. Taunk, L. Lin, L. Lee, P. Mohindra, K. Bradley, C. Fisher, E. Fields, M. Joyner (USA)	OC-071

World Congress of Brachytherapy

Proffered Papers: Proffered papers 6 - Verification and optimisation

10:30 - 11:30	Room C7
---------------	---------

	Chair: R. Cormack (USA) Co-chair: N. Nesvacil (Austria)	
10:30	First clinical results of integrated EM tracking for treatment verification in prostate BT <u>L. Van Heerden</u> , J. Schiphof-Godart, M. Christianen, J. Mens, M. Franckena, M. Maenhout, R. Rijnsdorp, L. Luthart, M. Hoogeman, I. Kolkman-Deurloo (The Netherlands)	OC-072
10:40	Catheter Reconstruction Limits of an Afterloader With EMT Capabilities <u>D. Tho</u> , L. Beaulieu (Canada)	OC-073
10:50	A multi-sensor-based dosimetry platform for real time source tracking in HDR brachytherapy <u>H.M. Linares Rosales</u> , J.G. Johansen, G. Kertzscher, K. Tanderup, L. Beaulieu, S. Beddar (Canada)	OC-074
11:00	Demonstration of 3D source tracking HDR brachytherapy treatment verification in a phantom <u>M. Hanlon</u> , R. Smith, V. Panettieri, J. Millar, R. Franich (Australia)	OC-075

11:10	Automated Plan Verification Software for Ultrasound-Planned High Dose Rate Prostate Brachytherapy <u>T. Harris</u> , C. Molodowitch, E. Sugar, D. O'Farrell, M. King, I. Buzurovic (USA)	OC-076
11:20	Fast Mixed Integer Optimization for High Dose Rate Brachytherapy <u>M. Antaki</u> , C.L. Deufel, S. Abbasinejad Enger (Canada)	OC-077

World Congress of Brachytherapy

Poster discussion: Poster discussion 2

10:30 - 11:30 Brachy Village: Poster Discussion Station

	Chair: D.N. Sharma (India) Co-chair: A. Gomez-Iturriaga (Spain)	
10:30	Contact X-Ray Brachytherapy for eyelid carcinoma: Efficacy and toxicity in 69 patients <u>S. Sumodhee</u> , K. Benezery, D. Baron, R. Natale, M. Gautier, C. Dejean, J. Gérard (France)	PD-078
10:35	Management of Non-Invasive Breast Cancer with Accelerated Partial Breast Irradiation Brachytherapy <u>M. Mills</u> , R. Diaz, R. Nanda, J. Wilson, T. Altoos, D. Caldwell, L. Stout, S. Dube, P. Blumencranz, K. Allen (USA)	PD-079
10:40	Spanish Brachytherapy Group Consensus on Accelerated Partial Breast Irradiation with interstitial BT <u>S. Pérez Echagüen</u> , C.J. Sanz Freire, J.L. Guinot Rodríguez, C. Gutiérrez Miguélez, P. Samper Ots, V. González Pérez, E. Villafranca Iturre, I. Modolell Farré, S. Pellejero Pellejero, M. Cambeiro Vázquez, G. Ossola Lentati (Spain)	PD-080

10:45	HDR Monotherapy for Low and Intermediate Risk Prostate Cancer in One or Two Fractions <u>V. Biryukov</u> , O. Lepilina, D. Sanin, A. Obukhov, N. Borysheva, O. Karyakin, S. Ivanov, A. Kaprin (Russian Federation)	PD-081
10:50	MRI-guided dose escalation to DIL with US-planned HDR prostate brachytherapy: a phase II study <u>J. Ding</u> , S. Tisseverasinghe, F. Bachand, J. Crook (Canada)	PD-082
10:55	Updated results of focal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer. <u>M. Van Son</u> , M. Peters, M. Moerland, J. Lagendijk, W. Eppinga, T. Shah, H. Ahmed, J. Van der Voort van Zyp (The Netherlands)	PD-083
11:00	17 years' experience of EBRT plus HDR brachytherapy boost in high risk prostate cancer patients <u>E. Vigneault</u> , D. Carignan, P. Després, S. Magnan, M. Froment, W. Foster, S. Aubin, M. Lavallée, F. Lacroix, A. Cantin, É. Poulin, A. Martin (Canada)	PD-084
11:05	Comparative Morbidity: TURP followed by HDR brachytherapy versus HDR brachytherapy alone. <u>B. Odei</u> , H. Hauswald, J.C. Rwigema, J. Wang, E. Ziel (USA)	PD-085
11:10	Prostatitis after HDR Brachytherapy Monotherapy: Evaluation of patients treated on the BRP 2 Trial <u>M. Jolicoeur</u> , T. Derashodian, T.V. Nguyen-Huyn, E. De Castro Hillmann, R. Heliou, G. Wakil, M. Nachabe, E. Antebi, M. Mondat (Canada)	PD-086
11:15	Does ADT benefit UIR prostate cancer patients treated with BT boost? A propensity-score analysis <u>L. Mendez</u> , K. Martell, A. Warner, C. Tseng, H. Chung, A. Loblaw, G. Rodrigues, G. Morton (Canada)	PD-087

11:20	Low Dose Rate versus High dose rate Brachytherapy boost in intermediate risk prostate cancer. <u>S. Rodríguez Villalba</u> , P. Monasor Denia, M.J. Pérez-Calatayud, J. Richart Sancho, J. Pérez-Calatayud, M. Santos Ortega (Spain)	PD-088
11:25	Efficacy of CT-guided 3D template for 125I seed brachytherapy in pelvic recurrent rectal cancer <u>L. Wang</u> , H. Wang, Y. Jiang, Z. Ji, F. Guo, P. Jiang, X. Li, Y. Chen, H. Sun, J. Fan, W. Li, X. Li, J. Wang (China)	PD-089

World Congress of Brachytherapy

Plenary Session: Training the Next Generation of Brachytherapists

11:40 - 11:55	Room C8
---------------	---------

11:40	Chair: B. Pieters (The Netherlands) Training the Next Generation of Brachytherapists <u>D. Petereit</u> (USA)	SP-090
-------	--	--------

World Congress of Brachytherapy

Award Lecture: Marie Curie Medal

12:00 - 12:30	Room C8
---------------	---------

12:00	Chair: B. Pieters (The Netherlands) Chair: D. Petereit (USA) Introduction Chair: F. Vicini (USA)
-------	--

12:05	Will Brachytherapy Survive the Radical Changes Facing Medicine? <u>A. Martinez</u> (USA)	SP-091
-------	--	--------

World Congress of Brachytherapy

Symposium: Single dose vs fractionated HDR monotherapy

14:00 - 15:15

Room C8

This session will review the fundamentals of HDR monotherapy for prostate cancer with an emphasis on single vs. fractionated definitive treatment schedules. The expert panel will cover several topics critical to modern practice including the radiobiologic and clinical rationale for different fractionation schedules and a summary of treatment outcomes, patterns of failure and associated toxicity profiles. This will be accompanied by a discussion of the relevant high level supporting evidence, technical aspects including focal dose escalation and consideration of risk group stratification, salvage therapies, and a comparison to LDR monotherapy. Finally, a look forward to future directions in HDR prostate brachytherapy will be provided.

Chair: A. Salgado (Chile)

Co-chair: B. Cox (USA)

14:00	Single dose HDR brachytherapy is safe for low-risk prostate cancer <u>P. Hoskin</u> (United Kingdom)	SP-092
14:18	Single dose HDR prostate brachytherapy and residual disease <u>G. Morton</u> (Canada)	SP-093
14:36	HDR prostate brachytherapy and fractionation; does it matter? <u>J. Millar</u> (Australia)	SP-094
14:54	LDR prostate brachytherapy is safe for every risk disease <u>B. Davis</u> (USA)	SP-095

World Congress of Brachytherapy

Symposium: 21st century brachytherapy: is it available, affordable and relevant?

14:00 - 15:15

Room C7

There are several reports of declining use of brachytherapy worldwide despite its well-documented advantages. Brachytherapy is often perceived to be resource-intensive and expensive and its role in the era of increasingly sophisticated external beam radiotherapy techniques has been questioned.

This session discusses some of the issues that influence availability and utilisation of brachytherapy. Topics include current status of cervix cancer brachytherapy availability worldwide and global initiatives to improve access, socio-economic factors impacting brachytherapy treatment trends in the United States, a literature review of time activity based costing studies of brachytherapy, and brachytherapy training and interest amongst European radiation oncology residents.

Chair: L.T. Tan (United Kingdom)

Co-chair: J.A. Polo Rubio (Austria)

14:00	Advocating global availability of cervical cancer brachytherapy <u>S. Chopra</u> (India)	SP-096
14:18	Brachytherapy Disparity and Challenges of Reimbursement in the United States <u>P. Orio</u> (USA)	SP-097
14:36	Utilizing time activity based costing to determine the real costs of brachytherapy <u>M. Kamrava</u> (USA)	SP-098
14:54	Motivating the next generation of brachytherapy trainees <u>A. Sturdza</u> , K. Tanderup, B. Pieters, I. Schulz-Jurgenliemk, L. Tan, R. Pötter, R. Nout, M. Kamrava (Austria)	SP-099

World Congress of Brachytherapy

Symposium: Head and Neck recurrences after full course Radiotherapy

15:45 - 17:00

Room C8

There are several options for treatment of 'local Head and neck recurrences after full course radiotherapy. Prof. Meyer talks about modern organ and function preservation surgery, which allows a volume reduction and mapping of the recurrence. Dr. Bonomo will give an overview about pattern of failure, selection of pts. for irradiation and the evidence for IMRT, SBRT and Protons. Finally Dr. Cambeiro Vazquez reports about the option of Brachytherapy. Limitations and experiences of inoperable recurrences, perioperative BT in combination with surgery and the outcome and toxicity compared to EBRT

Chair: P. Niehoff (Germany)

Co-chair: A. Budrukkar (India)

15:45	Why surgery? <u>J. Meyer</u> (Germany)	SP-100
16:10	Why EBRT? <u>P. Bonomo</u> (Italy)	SP-101
16:35	Why Brachytherapy? <u>M. Cambeiro</u> (Spain)	SP-102

World Congress of Brachytherapy

Symposium: Accelerated partial breast irradiation - Phase 3 trial results

15:45 - 17:00

Room C7

Chair: J. Hannoun-Levi (France)

Co-chair: J. Tang (Singapore)

15:45	Results of brachytherapy trials <u>V. Strnad</u> (Germany)	SP-103
16:03	Results of external beam radiotherapy trials <u>C. Coles</u> (United Kingdom)	SP-104

16:21	Results of IORT (Intra-Operative Radiation Therapy trials <u>R. Orecchia</u> (Italy)	SP-105
16:39	Ongoing clinical trials and future trends of APBI <u>D. Wazer</u> (USA)	SP-106

**Saturday
4 April
2020**



World Congress of Brachytherapy

Teaching Lecture: How to implement and execute an incident learning system

08:00 - 08:40

Room C8

Chair: J. Swamidas (India)

08:00 **How to implement and execute an incident learning system** SP-107

L. Fong de los Santos (USA)

World Congress of Brachytherapy

Symposium: Guidelines and recommendations in gynaecological cancers

08:45 - 10:00

Room C8

Chair: A. Klopp (USA)

Co-chair: T. Tamaki (Japan)

08:45 **IBS/GEC-ESTRO recommendations for CT based treatment of cervical cancer** SP-108

U. Mahantshetty (India)

09:03 **JASTRO recommendations for CT based brachytherapy for cervical cancer** SP-109

T. Ohno (Japan)

09:21 **GEC-ESTRO/IBS/ABS recommendations for treatment planning** SP-110

K. Tanderup, N. Nesvacil, U. Mahantshetty, M. Serban, J. Swamidas, A. De Leeuw, S. Beriwal, C. Yashar, M. Harkenrider, C. Kirisits, P. Petric, I. Jürgenliemk-Schulz, N. Lavanya, A. Dheera, R. Pötter (Denmark)

09:39 **GEC-ESTRO/ABS/CARO recommendations on target definition in vaginal recurrences** SP-111

R. Nout (The Netherlands)

World Congress of Brachytherapy

Debate: Optimal treatment for periorificial high risk non-melanoma skin cancer

08:45 - 10:00

Room C7

Non-melanoma skin cancer incidence is rapidly rising worldwide. When surgery is not feasible (e.g. poor performance patient, significant co-morbidities), or could result in unacceptable functional and / or cosmesis morbidity, radiotherapy can offer an excellent and versatile non-surgical option. Radiotherapy can be delivered as external beam or brachytherapy. In this debate expert speakers from surgical and radiation specialities will provide arguments for the surgery and radiotherapy in the management of NMSC, with emphasis on the need of multidisciplinary cooperation. The debate will be focused on two highly cosmetically sensitive facial locations: lip and nose. The debate will be supported by published results and guidelines in the field.

Chair: P. Devlin (USA)

Co-chair: A. Rembielak (United Kingdom)

08:45 **This house believes that surgery should be considered for lip high risk non-melanoma skin cancer** SP-112

C. Newlands (United Kingdom)

09:03 **This house believes that radiotherapy/brachytherapy should be considered for lip high risk non-melanoma skin cancer** SP-113

A. Budrukkar (India)

09:21 **This house believes that surgery should be considered for nose high risk non-melanoma skin cancer** SP-114

F. Bussu (Italy)

09:39 **Brachytherapy a useful tool for nasal and peri-nasal tumors** SP-115

B. Johansson, L. Karlsson (Sweden)

World Congress of Brachytherapy

Proffered Papers: Proffered papers 7 - Prostate outcome and dosimetry

10:30 - 11:30

Room C8

Chair: H. Chung (Canada)

Co-chair: G. Bucci (Australia)

- 10:30 **One fraction HDR vs. LDR brachytherapy in early prostate cancer. A prospective, randomized study.** OC-116
P. Ágoston, T. Major, K. Jorgo, G. Fröhlich, C. Polgár (Hungary)
- 10:40 **The radiosensitivity index predicts benefit from HDR brachytherapy in high-risk prostate cancer** OC-117
N. Thiruthaneeswaran, B.A.S. Bibby, R. Pereira, E. More, H. Denley, A. Henry, J. Wylie, P. Hoskin, R. Bristow, A. Choudhury, C. West (United Kingdom)
- 10:50 **Dosimetry of local failure with single dose 19Gy high-dose-rate brachytherapy for prostate cancer** OC-118
S. Armstrong, Y. Tsang, G. Lowe, H. Tharmalingam, P. Ostler, R. Alonzi, R. Hughes, P. Hoskin (United Kingdom)
- 11:00 **Comparison of SBRT, brachytherapy, and dose-escalated EBRT for localized prostate cancer** OC-119
A. Lee, K. Nguyen, S. Patel, A. Supariwala, P. Venkat, A. Chakravorty, E. Lin, C. Zarate, J. Demanes, A. Chang (USA)
- 11:10 **Can all prostate cancer patients achieve a PSA nadir ≤ 0.2 after brachytherapy-based radiotherapy?** OC-120
T. Soyano, A. Yorozu, S. Sutani, N. Natsume, Y. Shiraishi, K. Toya, S. Saito (Japan)
- 11:20 **Salvage LDR Prostate Brachytherapy: Results of NRG/RTOG-0526 Trial for Local Recurrence after EBRT** OC-121
J. Crook, J. Rodgers, T. Pisansky, E. Trabulsi, M. Amin, W. Bice, G. Morton, N. Pervez, E. Vigneault, C. Catton, J. Michalski, M. Roach, D. Beyer, P. Rossi, E. Horwitz, V. Donavanik, H. Sandler (Canada)

World Congress of Brachytherapy

Proffered Papers: Proffered papers 8 - Imaging physics and dosimetry

10:30 - 11:30

Room C7

Chair: F. Mourtada (USA)

Co-chair: W.Y.V. Lee (Hong Kong (SAR) China)

10:30 **GEC-ESTRO / ACROP recommendations for Quality Assurance of Ultrasound in Brachytherapy** OC-122

F. Siebert, C. Kirisits, T. Paulsen Hellebust, D. Baltas, F. Verhaegen, S. Camps, B. Pieters, G. Kovács, B. Thomadsen (Germany)

10:40 **Parallel imaging compressed sensing for prostate MRI without an endorectal coil: a prospective study** OC-123

J. Sanders, S. Frank, A. Venkatesan, T. Bathala, C. Tang, R. Kudchadker, T. Bruno, M. Pagel, J. Ma (USA)

10:50 **Oxygen Sensing HDR-Brachytherapy Catheters with an Intra-Lumen MRI Receive Coil** OC-124

R. Cormack, G. Ekchian, J. Tokuda, C. Frangieh, L. Lee, M. Cima (USA)

11:00 **Impact of choices in dosimetric calculation method for high dose rate brachytherapy of breast cancer** OC-125

V. Turgeon, B. Bahoric, M. Morcos, S.A. Enger (Canada)

11:10 **Influence of an US probe on in-vivo source tracking with an imaging panel in HDR brachytherapy.** OC-126

C. Van Beveren, G.P. Fonseca, M. Bellezzo, F. Verhaegen (The Netherlands)

11:20 **In-vivo film dosimetry indicates a role for model-based algorithms in HDR surface brachytherapy** OC-127

S. Aldelaijan, D.A. O'Farrell, T.C. Harris, R.A. Cormack, J.P. Seuntjens, S. Devic, P.M. Devlin, I.M. Buzurovic (USA)

World Congress of Brachytherapy

Poster discussion: Poster discussion 3

10:30 - 11:30

Brachy Village: Poster Discussion Station

Chair: M. Schmid (Austria)

Co-chair: tbc

10:30 **Results from the First Spanish National Survey on** PD-128

Epiescleral Brachytherapy for Uveal Melanoma

I. Rodriguez, P. Diezhandino Garcia, J. De Frutos Baraja, M.A. Saornil Álvarez, A. Slocker, I. Sancho, J.M. Caminal Mitjana, F. Celada Álvarez, J. Pérez Calatayud, R. Martínez Costa, F.D.A. Carrasco Peña, J.A. Terron Leon, M.I. Relimpio Lopez, A. Gómez Caamaño, J. Mosquera Sueiro, A. Piñeiro, J.L. Guinot Rodriguez, V. De los Dolores Alemany, J. Mataix Boronat, E. Corredoira Silva, M. Asencio Durán, E. Villafranca Iturre (Spain)

10:35 **Cost-utility analysis of radiation strategies in the** PD-129

management of intermediate-risk prostate cancer

J. Helou, D. Naimark, G. Morton, N. Sanmamed, C. Catton, J. Raphael, A. Loblaw (Canada)

10:40 **Salvage HDR-Endobronchial Brachytherapy for** PD-130

Endobronchial Recurrence of Non-Small Cell Lung Cancer

T. Soror, G. Kovács, V. Fürschke, M. Ismail, H. Badakhshi (Germany)

10:45 **106Ru eye plaque brachytherapy : the effect of plaque position on OARs absorbed doses** PD-131

F. Itta, R. Liuzzi, A. Farella, A. Breve, G. Cennamo, L. Cella, C. Oliviero, C. Feoli, M. Conson, R. Pacelli, S. Clemente (Italy)

10:50 **Title: Adjuvant electronic brachytherapy for patients with endometrial cancer.** PD-132

M. Cerrolaza, A. Campos, A. Méndez, M. Gascón, A. Miranda, S. Flamarique, S. Lozares, R. Ibañez (Spain)

10:55 **The state of stage I uterine cancers in the United States: does race impact care or survival?** PD-133

Z. Horne, S. Teterichko, R. Wegner, S. Hasan, S. Crafton, E. Miller, T. Krivak, P. Sukumvanich, S. Beriwal (USA)

11:00 3D printed individual template based 192Ir interstitial brachytherapy for central recurrent GYN	PD-134
<u>P. Jiang</u> , Q. Ang, J. Weijuan, W. Junjie, S. Haitao, Z. Xlle, W. Panfeng, D. Junyao, W. Songbo (China)	
11:05 Hybrid Brachytherapy in Locally Advanced Cervical Cancer:Impact of Dose and Tumor Volume Metrics	PD-135
<u>A. Rivera</u> , M. Wassel, P. Brodin, R. Yaparpalvi, C. Velten, R. Kabarriti, M. Garg, S. Kalnicki, K.J. Mehta (USA)	
11:10 Evaluation of an Intelligent Virtual Treatment Planner for Cervical Cancer Brachytherapy	PD-136
<u>C. Shen</u> , Y. Gonzalez, K. Albuquerque, X. Jia (USA)	
11:15 Sexual Toxicity in Cervix Cancer Survivors Treated with Chemo-Radiation and MR-guided Brachytherapy	PD-137
J. Conway, L. Conroy, S. Ferguson, A. Zia, A. Liu, J. Weiss, A. Rink, <u>C. Jennifer</u> (Canada)	
11:20 Vaginal dose de-escalation in cervix brachytherapy	PD-138
<u>L. Hallett</u> , G. Aldred, L. Lane (United Kingdom)	
11:25 Evaluation of hydrogel for dose escalation and as a tissue marker in gynecologic brachytherapy	PD-139
<u>M. Morcos</u> , R.K. Bhatia, A.N. Viswanathan (USA)	

World Congress of Brachytherapy

Award Lecture: GEC-ESTRO Best Junior Presentation and 5 Best Poster Presentations

11:40 - 12:40 Room C8

Chair: tbc

Co-chair: B. Erickson (USA)

11:40 Does Dose to the Ureter Predict for Ureteral Stenosis? - Analysis of 3D MRI-Based Brachytherapy	PD-140
<u>J. Rodríguez-López (awardee)</u> , A. Mojica-Márquez, D. Ling, H. Kim, A. Patel, C. Houser, S. Beriwal (USA)	
11:58 Characterization of intracavitary/interstitial brachytherapy using oblique needles in cervix cancer	PD-141
<u>M. Serban</u> , L. Fokdal, S. Kynde Nielsen, S. Bjerre Hokland, A. Hansen, H. Spejlborg, S. Rylander, P. Petric, J. Lindegaard, K. Tanderup (Denmark)	

- | | |
|--|--------|
| 12:03 Machine Learning Analysis of Salvage HDR Prostate Brachytherapy-A Validation Study
<u>S. Wu</u> , A. Wong, K. Shinohara, A. Chang, A. Cunha, G. Valdes, T. Solberg, I. Hsu (USA) | PD-142 |
| 12:08 In-vivo Dosimetry for Validation of Real-Time Prostate Brachytherapy: Clinical Trial Outcomes
<u>D. Cutajar</u> , J. Poder, A. Howie, R. Brown, K. Enari, K. Schreiber, M. Carrara, A. Rosenfeld, A. Bece, D. Malouf, J. Bucci (Australia) | PD-143 |
| 12:13 Computer aided brachytherapy: assisting the practice of prostate brachytherapy with machine learning
<u>J. Sanders</u> , A. Venkatesan, J. Davis, R. Kudchadker, C. Tang, T. Bruno, J. Ma, S. Frank (USA) | PD-144 |
| 12:18 Efficacy and Pattern of Failure - HDR Brachytherapy for Penile Cancer: Single-Institution Experience
<u>S. Kellas-sleczka</u> , P. Wojcieszek, M. Szlag, A. Cholewka, M. Wesolowski, M. Slezak, M. Fijalkowski, A. Andrejczuk, T. Krzysztofiak, P. Lelek, M. Stankiewicz, B. Bialas (Poland) | PD-145 |

World Congress of Brachytherapy

Proffered Papers: Proffered papers 9 - From research to practice

11:40 - 12:40

Room C7

Chair: H. Marsiglia (Chile)

Co-chair: B. Johansson (Sweden)

- 11:40 **Comparative study of brachytherapy vs. radical cystectomy for cT1-2 muscle-invasive bladder cancer** OC-146
C.S. Voskuilen, J. Bosschieter, E. Van Werkhoven, K. HendrickSEN, A.N. Vis, F.J. Pos, M. Burger, A. Bex, H.G. Van der Poel, L.M. Moonen, S. Horenblas, J.A. Nieuwenhuijzen, B. Pieters, B.W. Van Rhijn (The Netherlands)

11:50 **Dose-volume effect relationships for rectal morbidity after brachytherapy for pediatric cancers.** OC-147
E. Romano, R. Simon, V. Martin, S. Bolle, M. Andraud, G. Boulle, M. Kissel, T. Kumar, H. Martelli, F. Guerin, E. Deutsch, C. Haie-Meder, C. Chargari (France)

12:00	Clinical outcomes and Toxicity profile with IMRT or Brachytherapy boost in oropharyngeal malignancy	OC-148
	<u>V. Pareek</u> , R. Bhalavat, M. Chandra, L. Nellore, K. George, D. Borade (India)	
12:10	Correlation between Radiation-induced Foci from 192Ir Brachytherapy and Nuclei Size Distribution	OC-149
	<u>B. Behmand</u> , Y. Kamio, M. D.C. Evans, S. A. Enger (Canada)	
12:20	Genomic markers of response to chemoradiotherapy in cervical cancer	OC-150
	<u>G. Alban</u> , B. Rawal, J. Adleman, M. King, J. Liu, U. Matulonis, J. Pretz, L. Singer, L. Lee (Brazil)	
12:30	Real world interpretation of GEC-ESTRO image-guided brachytherapy recommendations for cervix cancer	OC-151
	<u>P. Diez</u> , J. Bourner, A. Sharp, P.J. Hoskin, M. McCormack (United Kingdom)	

World Congress of Brachytherapy
Symposium: Gastrointestinal brachytherapy

14:15 - 15:30 Room C8

Chair: A. Taggar (Canada)

Co-chair: R. Nout (The Netherlands)

14:15	Can Imaging technique affect treatment planning in brachytherapy of rectal and anal canal carcinomas?	SP-152
	<u>J. Gérard</u> , c. Dejean, k. Benezery, a. Falk, l. Montagne, m. Gauthier, j. Hannoun levi (france)	

14:40	Gallbladder: status of the art	SP-153
	<u>P. Devlin</u> (USA)	

15:05	Oesophagus: An orphan topic?	SP-154
	<u>A. Rovirosa</u> (Spain)	

World Congress of Brachytherapy

Symposium: Brachytherapy physics 2030 – Adaptive dose delivery and planning

14:15 - 15:30

Room C7

In this session the latest developments and advancements on adaptive dose planning and delivery are discussed. The first presentation will highlight the potential and limitations of image registration in treatment planning, in particular for gynaecological brachytherapy, with special attention for the challenges associated with deformable image registration in contouring and dose accumulation. Next, the role of automation in the treatment planning and delivery process will be handled. Automation is increasingly finding its way into clinical practice in terms of applicator digitization, plan optimization, quality assurance and plan documentation. This will affect the role of physicists in treatment planning as well as the interaction with physicians, coming with a change in practice. Finally, an introduction will be given on artificial intelligence, machine learning and big data, and the potential role it can directly play in brachytherapy applications such as contouring and dosimetric planning.

Chair: M. De Brabandere (Belgium)

Co-chair: A. Haworth (Australia)

14:15 **Image registration, Automated segmentation, and Dose Summation** SP-155

j. Swamidas, c. Kirisits, m. De brabandere, t. Hellebust, f. Siebert, k. Tanderup (india)

14:33 **Automation for treatment planning and quality assurance (actual advancements)** SP-156

C. Deufel (USA)

14:51 **The role of physics, dosimetry, and physicians in an era of automation: how will our practice change?** SP-157

J.A.M. Cunha (USA)

15:09 **What is this thing called AI and how can it help brachytherapy?** SP-158

P. Bosman (The Netherlands)

World Congress of Brachytherapy

Proffered Papers: Proffered papers 10 - Utilisation, training and developments in Gyn BT

16:00 - 17:15

Room C8

Chair: A. Rovirosa (Spain)

Co-chair: T. Ohno (Japan)

16:00 **Do We Need Adjuvant Brachytherapy for Stage IA High Grade Endometrial Cancer?** OC-159

H. Musunuru, R. Mackenzy, B. Orr, S. Beriwal (USA)

16:10 **Declining brachytherapy utilization for cervical cancer patients - have we reversed the trend?** OC-160

S. Beriwal, M. Schad, A. Patel, S. Glaser, G. Balasubramani, T. Showalter, J. Vargo (USA)

16:20 **Pelvic radiation and boost at separate facilities associated with cervical cancer treatment delays** OC-161

R. Li, E. Germino, Y. Chen, Z. Horne, J.A. Vargo, S. Glaser (USA)

16:30 **Cervical cancer brachytherapy training by 3D printing tissue equivalent patient anatomy from DICOMs** OC-162

J. McGee, M. McGee, T. Ralph, S.M. Pieta (USA)

16:40 **Reading Between the Voxels: Radiomic Predictors of Progression-Free Survival in Cervical Cancer** OC-163

R. Zeitlin, H. Saeed, D. Schott, Y. Zhang, N. Morrow, P. Prior, J. Rownd, E. Paulson, X.A. Li, B. Erickson, M. Bedi (USA)

16:50 **In-vitro determination of radiobiological parameter values used in cervical cancer brachytherapy** OC-164

B. Chow, K. Nanda, B. Warkentin, F. Huang, A. Gamper, G. Menon (Canada)

World Congress of Brachytherapy

Symposium: Brachytherapy : Strategies to improve utilization in various sites and settings

16:00 - 17:15

Room C7

Chair: T. Merino (Chile)

Co-chair: S. Van Dyk (Australia)

16:00 **GEC-ESTRO viewpoint in strategies to increase brachytherapy utilization** SP-165
B. Pieters (The Netherlands)

16:18 **Brachytherapy: Strategies to improve utilization in various sites and settings (ABS Viewpoint)** SP-166
C. Yashar (USA)

16:36 **Brachytherapy: Strategies to improve utilization in various sites and settings: (IBS Viewpoint)** SP-167
D.N. Sharma (India)

16:54 **Brachytherapy: Strategies to improve utilization in various sites and settings (ALATRO viewpoint)** SP-168

G.J. Sarria Bardales, D.A. Martinez Perez, R. Del Castillo Pacora (Peru)

World Congress of Brachytherapy

Plenary Session: Closing remarks

17:15 - 17:30

Room C8

17:15 **Closing remarks**

B. Pieters (The Netherlands)

Posters



World Congress of Brachytherapy
Poster: Brachytherapy: Breast

Contralateral Breast Dose from Whole and Partial Breast Radiation Techniques	PO-169
<u>S. Dutta</u> , E. Aliotta, B. Libby, T. Showalter, S. Showalter, E. Janowski (USA)	
Clinical and cosmesis results of breast cancer intraoperative interstitial brachytherapy	PO-170
<u>B.J. Salazar Zuñiga</u> , M. Colmenero, L. Juan, I. Alda, A. Milanes, R. Prados, J. Perez-Regadera (Spain)	
Dosimetric impact of differential CTV margins for APBI following interstitial brachytherapy	PO-171
<u>T. Wadasadawala</u> , A. Kumar, K. Joshi, L. Scaria, R. Pathak, R. Sarin (India)	
Utility of Genomic Testing for Early Stage Breast Cancer Patients Treated with APBI Brachytherapy	PO-172
<u>M. Mills</u> , R. Diaz, R. Nanda, J. Wilson, T. Altoos, D. Caldwell, L. Stout, S. Dube, K. Allen, P. Blumencranz (USA)	
External beam radiotherapy and brachytherapy for partial breast irradiation: dosimetric comparison.	PO-173
<u>I. Akulova</u> , S. Novikov, Z. Bryantseva, J. Melnik, S. Kanaev (Russian Federation)	
High dose rate brachytherapy versus electron boost for tumor bed after breast conserving therapy.	PO-174
<u>Z. Bryantseva</u> , S. Novikov, I. Akulova, J. Melnik, S. Kanaev (Russian Federation)	
Radioactive Iodine-125 Seeds Implantation for Unresectable Early-stage Non-Small Cell Lung Cancer	PO-175
<u>Z. Ji</u> , B. Huo, Z. Wang, K. Zhang, Y. Song, J. Wang (China)	
Verification of Basal Dose & Treatment Dose for a Virtual Tumor by Paris System in Interstitial BT.	PO-176
<u>K. Afrin</u> , H.A. Azhari, G.Z. Abu, M.K. Kazi (Bangladesh)	

Effects of uncertainty with Strut Adjusted Volume Implant applicator in Japan.	PO-177
<u>K. Miyaura</u> , T. Fujii, S. Kubo, H. Shinjoh, M. Kato, K. Toyofuku, A. Niiya, R. Kobayashi, Y. Ozawa, K. Murakami, M. Morota, A. Imai, Y. Ito, Y. Kagami (Japan)	
Breast Intra-operative Radiotherapy using the new Contact X Ray Brachytherapy Papillon+ tm system	PO-178
<u>M. Chand-Fouché</u> , D. Lam Cham Kee, J. Gal, C. Dejean, M. Gautier, E. Barranger, J. Gérard, J. Hannoun-Lévi (France)	
Phase II Trial of APBI using Non-Invasive Image-Guided Breast Brachytherapy (NIBB): Final Results	PO-179
<u>J. Hepel</u> , K. Leonard, S. Sha, T. Graves, D. Wiggins, D. Mastras, A. Pittier, B. Brown University Oncology Research Group, D. Wazer (USA)	
Quality of Life Assessment comparison between APBI and WBI in Breast Conserving surgery	PO-180
<u>V. Pareek</u> , R. Bhalavat, M. Chandra, L. Nellore, K. George, D. Borade (India)	
Accelerated partial breast irradiation with HDR brachytherapy in elderly breast cancer patients	PO-181
<u>P. Lelek</u> , S. Kellas-Ślęczka, T. Krzysztofiak, M. Stankiewicz, M. Fijałkowski, P. Wojcieszek (Poland)	
Impact of risk factors for long-term breast recurrence of APBI with interstitial HDR brachytherapy.	PO-182
<u>J. Guinot</u> , O. Revilla, M. Moreno-Manzanaro, M. Martí, L. Gonzalez-Vallejo, P. Blasco-Valls, M. Peña, B. Quiles, A. La Rosa, M.I. Tortajada, M.A. Santos, L. Arribas (Spain)	

World Congress of Brachytherapy
Poster: Brachytherapy: Gynaecology

Combined ICBT and needles in Advanced Cancer cervix using homemade template -A poor man's technique.	PO-183
<u>S.K. Mohanty</u> , D. Pradhan, N. Madhani, C. Shah, S. Dave, H. Ashar, P. Gurung, T. Balan Page, D. V, V.K. Gupta (India)	

Balloon intravaginal packing reduces rectal dose and toxicity in brachytherapy for cervical cancer	PO-184
<u>J. Lee</u> , S.J. Stephens, J. Chang, S. Meltsner, O. Craciunescu, J. Chino (USA)	
Intracavitary electronic brachytherapy (e-BT) for gynecological malignancies	PO-185
<u>G. Sarria</u> , E. Sperk, F. Wenz, F. Schneider, Y. Abo-Madyan, F.A. Giordano, M. Ehmann (Germany)	
Tandem design for MRI-planned vaginal, cervical and endometrial brachytherapy	PO-186
<u>A. Beiki-Ardakani</u> , I. Yeung, A. Kirilova, A. Rink, J. Borg, R. Weersink, M. Milosevic, J. Jezioranski (Canada)	
Clinical outcomes for endometrial cancer patients treated with adjuvant vaginal vault brachytherapy	PO-187
<u>M. Zahra</u> , A. Stillie, W. Keough (United Kingdom)	
Survival in Patients with Cervical Cancer in the East of Iran from 2001 to 2016	PO-188
<u>S.A. Javadinia</u> , A. Fanipakdel, S. Hosseini, S. Shahidsales (Iran Islamic Republic of)	
Kelowna GYN template-based high-dose rate interstitial brachytherapy: design and dosimetric results	PO-189
<u>J. Shiao</u> , D.E. Holt, D. Westerley, T.P. Robin, C.M. Fisher (USA)	
CT-guided Pelvic Lymph Nodal Brachytherapy for Gynecological Malignancies	PO-190
<u>H. Kunogi</u> , I. Hsu, N. Yamaguchi, K. Sasai (Japan)	
Feasibility and Outcomes for Cervical Cancer Patients Treated with Hybrid Brachytherapy Applicators	PO-191
<u>A. Keller</u> , H. Kim, C.J. Houser, J. Rodriguez-Lopez, A. Patel, P. Sukumvanich, J.L. Berger, M.M. Boisen, R. Edwards, S.E. Taylor, M.B. Courtney-Brooks, A.B. Olawaiye, B.C. Orr, S. Beriwal (USA)	
Prospective Multi-Institutional Proficiency-Based Cervical Cancer Brachytherapy Training Program	PO-192
<u>E. Fields</u> , K. Albuquerque, S. Damast, N. Taunk, M. Joyner, L. Lin, L. Singer (USA)	
A prediction model of intracavitary/interstitial brachytherapy based on artificial neural network	PO-193
<u>G. Cheng</u> , Z. Ning, G. Xin (China)	

Spacer Gel Reduced Incidence of Rectal Bleeding in Brachytherapy for Gynecological Malignancies	PO-194
<u>N. Murakami</u> , S. Nakamura, T. Kashihara, T. Kato, K. Takahashi, K. Inaba, K. Okuma, H. Igaki, Y. Nakayama, R. Galalae, J. Itami (Japan)	
HDR GYN cervix brachytherapy using Se-75	PO-195
<u>J. Dupere</u> , J. J Munro III, D. C Medich (USA)	
Consensus on 3D-vaginal-cuff Brachytherapy from the Spanish Brachytherapy SEOR and SEFM groups.	PO-196
<u>P.M. Samper Ots</u> , A. Rovirosa Casino, A. Herreros Martínez, R. Polo Cezón, C. Gutiérrez Minguélez, J. Anchuelo Latorre, I. Rodríguez Rodríguez, S. Córdoba Largo, S. Pérez Echagüen, S. Rodríguez Villalba, J. Pérez Calatayud, C. Sanz Freire, F. Clemente Gutiérrez, D. De las Peñas Cabrera, E. Villafranca Iturre (Spain)	
A review of brachytherapy for vaginal malignancies using customised moulds and interstitial needles	PO-197
<u>E. Sullivan</u> , E. Flower, G. Busutil, J. Chard, S. Zanjani, D. Thwaites, V. Do (Australia)	
Analysis of cost effectiveness of inpatient vs. outpatient based interstitial vaginal brachytherapy	PO-198
<u>S. Azghadi</u> , A. Moran, B.M. Palo, D. San, E. Sevier, J.L. O'Malley, M. Adams, M.E. Kit, J.Y. Uy, R.K. Valicenti, X. Zhao (USA)	
Exploring Brachytherapy Educational Needs of Cervical Cancer Patients	PO-199
<u>C. Jennifer</u> , A. Julius, J. Manhertz, C. Heck, K. Chan, K. Lawrie, N. Quartey, J. Papadakos (Canada)	
Excellent Outcomes with CT-Based HDR Brachytherapy for Locally Advanced Cervical Cancer	PO-200
<u>J. Shiao</u> , D.E. Holt, T.P. Robin, C.M. Fisher (USA)	
Brachytherapy for locally advanced cervical cancer: UK service providers' views on improving care	PO-201
<u>P. Humphrey</u> , E. Dures, P. Hoskin, F. Cramp (United Kingdom)	
Sparing OaR with Hydrogel spacer (TraceIT) in LACC: dosimetric improvement and toxicity.	PO-202
<u>D. Najjari Jamal</u> , C. Gutiérrez Miguelez, L. Martin Cardona, A. Slocker Escarpa, P.S. Francisco, G. Rodriguez Abenoza, S. Moreno Almagro, M. Garcia Casellas, I. Visus Fernandez De Manzanos, F. Guedea Edo (Spain)	

Integrated MRI-guided intraoperative brachytherapy planning and treatment for cervical cancer	PO-203
<u>E. Leung</u> , L. D'Alimonte, A. Taggar, E. Barnes, E. Donovan, L. Barbera, A. Ravi (Canada)	
Indirect Excess Dose Volume Ratio (iRex): A Novel Predictor with Risk Reclassification from D2cc	PO-204
<u>T. Prasarteree</u> , P. Dankulchai (Thailand)	
Deformable registration for HDR cervix: Evaluation of deformation techniques for dose accumulation	PO-205
<u>V. Narayana</u> , V. Kumar, P. Wang (USA)	
Efficacy of radiation therapy combined with high dose rate brachytherapy in advanced cervical cancer	PO-206
<u>B. Sun</u> , Y. Xiu, F. Meng, J. Ou, Z. Wang, J. Du, K. Zhao, Y. Wang, Z. Chen, Q. Tian (China)	
Hypnosedation for endocavitary uterovaginal applications: a pilot study	PO-207
<u>M. Kissel</u> , M. Andraud, A. Duhamel, G. Boulle, E. Romano, S. Achkar, R. Bourdais, M. Ta, A. Pounou, T. Kumar, B. Celestin, L. Bordenave, V. Billard, C. Haie-Meder, C. Chargari (France)	
Intracavitary brachytherapy for endometrial carcinoma: institutional experience with Co-60 HDR.	PO-208
<u>J.A. Dominguez Rullan</u> , T. Muñoz Migueláñez, R. Colmenares Fernández, M. Martín Sánchez, M. Cámera Gallego, S. Sancho García (Spain)	
Clinical outcomes of computed tomography-based HDR brachytherapy in locally advanced cervical cancer	PO-209
<u>P. Chitmanee</u> (Thailand)	
Preplanning strategy for Venezia applicator in gynecological cancer treatment: a proof of principle	PO-210
<u>D. Te Lindert</u> , D.L.J. Barten, K.A. Hinnen, B.R. Pieters, H.G. Westerveld (The Netherlands)	
Vaginal wall dose between various vaginal brachytherapy in GYN cancer: phantom case	PO-211
<u>R. Kim</u> , S. Shen (USA)	
Survival of Stage IIB-IVA Cervical Cancer after Definitive CRT and HDR 60Co Intracavitary BT	PO-212
<u>S.A. Javadinia</u> , M. Masoudian, F. Homaei Shandiz (Iran Islamic Republic of)	

Outcomes after Co-60 HDR brachytherapy for cervical cancer in a tertiary hospital in the Philippines	PO-213
<u>R.E. Cereno</u> , B. Yap, L. Chavez, M.J. Germar, M. Eala, E.JR. Fragante (Philippines)	
Practice patterns in brachytherapy for cervical cancer in the Philippines: a national survey	PO-214
<u>R.E. Cereno</u> , J.P. Cañal (Philippines)	
Applicator-guided SBRT boost combined with intracavitary brachytherapy for advanced cervical cancer	PO-215
<u>C. Constantinescu</u> , N. Jastaniyah, S. Wadi-Ramahi, A. Nobah (Saudi Arabia)	
Intraoperative Brachytherapy (HDR-IOBT) in advanced or recurrence gynecologic cancer.	PO-216
<u>A.E. Villafranca Iturre</u> , I. Visus, A. Sola, P. Navarrete, M. Barrado, S. Pellejero, N. Fuentemilla, J.C. Muruzabal, S. Aguirre, C. Tauste, M. Rico, E. Martinez (Spain)	
Clinical outcomes for cervical cancer treated with MRI-based brachytherapy: A Japanese experience	PO-217
<u>K. Yoshida</u> , S. Seno, M. Omoteda, R. Nishikawa, H. Akasaka, D. Miyawaki, K. Kyotani, H. Sato, Y. Ebina, H. Yamada, R. Sasaki (Japan)	
3D-printed template-assisted, CT-guided I-125 seed brachytherapy in recurrent gynecological cancer	PO-218
<u>Y. Liu</u> , J. Ping, J. Yuliang, Z. Haichen, Q. Ang, J. Zhe, G. Fuxin, S. Haitao, L. Xu, T. Suqing, L. Weiyan, F. Jinghong, T. Bin, W. Lu, Z. Lijuan, W. Junjie (China)	
UK audit of target volume and organ at risk delineation and dose optimisation in cervix radiotherapy	PO-219
<u>J. Cannon</u> , P. Bownes, J. Mason, R. Cooper (United Kingdom)	
CT-guided 125I interstitial brachytherapy for vaginal recurrence cervical cancer after radiotherapy	PO-220
<u>H. Bin</u> , H. Xiaodong, W. Lei, W. Haitao, C. Shude (China)	
Needle localization in MRI-guided gynecological brachytherapy using a PETRA sequence	PO-221
<u>E. Kaza</u> , R. Cormack, I. Buzurovic (USA)	
Is mismatch repair deficiency prognostic for recurrent endometrioid endometrial cancer?	PO-222
<u>G. Alban</u> , J. Adleman, J. Pretz, L. Singer, M. King, L. Lee (Brazil)	

Design of 3D-printed sleeves to upgrade the Mick applicator for combined IC/IS GYN HDR brachytherapy	PO-223
M. Roy, <u>Y. Kamio</u> , M. Barkati, L. Morgan, B. Basaric, S.A. Enger, F. De Blois (Canada)	
Physical exam-based plan as possible surrogate for GEC-ESTRO-based IGBT plan for cervical cancer	PO-224
<u>E. Inocencio</u> , R.E. Cereno, H.C. Co (Philippines)	
Hybrid Brachytherapy in locally advanced Cervical cancer: A Survival and toxicity profile assessment	PO-225
<u>V. Pareek</u> , M. Chandra, R. Bhalavat, L. Nellore, K. George, D. Borade (India)	
Impact of Counselling on Patient reported sexual adjustment following cervical cancer management	PO-226
<u>V. Pareek</u> , M. Chandra, R. Bhalavat, L. Nellore, K. George, U. Ambekar, P.L. Iyer (India)	
Evaluation of dosimetric effects of central shielding technique in radiotherapy for Cervical Cancer	PO-227
<u>S. Seno</u> , Y. Kenji, A. Hiroaki, O. Mayumi, K. Katsusuke, N. Ryo, K. Hiroki, K. Hikaru, I. Takeaki, M. Daisuke, S. Ryohei (Japan)	
Role of brachytherapy in neuroendocrine tumours of cervix:A single institution experience from India	PO-228
<u>A.S. Jayraj</u> , D. Sharma, S. Kumar (India)	
Endometrial treatments with electronic brachytherapy. Comparison to Ir192 and Co60 HDR sources.	PO-229
<u>S. Lozares</u> , A. Gandía, S. Jiménez, V. Alba, M. Hernández, D. Villa, J.A. Font (Spain)	
Optimizing vaginal cuff brachytherapy planning: 3D - plan or not to plan at all?	PO-230
<u>J. Palmgren</u> , J. Seppälä, M. Anttila (Finland)	
Streamlining treatment of cervical cancer: The dosimetric impact of decay and treat in HDR planning	PO-231
<u>E. Jaworski</u> , A. Moncion, K. Vineberg, D. Owen, L. Young, V. Narayana, E. Abu-Isa, J. Chan, K. Maturen, L. McNew, P. Wang, S. Jolly, J. Prisciandaro (USA)	
Optimization of vaginal cuff HDR BT planning processes for patientes treated with ovoid applicator	PO-232
<u>F. Solinhac</u> , D. Martin, C. Furstoss, P. Munger (Canada)	

Does point based brachytherapy in cervical cancer have a place in the IGABT era?	PO-233
<u>B. Rai</u> , A. Gupta, T. Dey, A. Oinam, D. Kumar, S. Gy, S. Ghoshal (India)	
The Implementation of Radiographer led Vaginal Vault Brachytherapy using Rotterdam Applicators.	PO-234
<u>R. Farrell</u> (United Kingdom)	
Needle-free intensity modulated brachytherapy compared to Venezia brachytherapy for cervical cancer	PO-235
<u>M. Morcos</u> , A.N. Viswanathan, S.A. Enger (Canada)	
Radiation therapy treatment of Older Women With Endometrial Cancer treated in Navarre	PO-236
<u>A. Martin</u> , E. Villafranca, A. Sola, M. Rodriguez, L. Rosas, A. Gómez, P. Navarrete, J.C. Muruzábal, S. Aguirre, C. Tauste, S. Lapeña, O. Tarrío, N. Fuentemilla, S. Pellejero, E. Martinez (Spain)	
Co60 versus Ir192 in HDR Brachytherapy in Carcinoma Cervix - A Randomised Controlled Study	PO-237
<u>N.M. Kiran</u> , B. Rai, R. Miriyala, A.S. Oinam, D. Kumar, R. Bagga, S. Ghoshal (India)	
3D-printing Vaginal Applicator assist HDR ICBT as Re-irradiation for Recurrent Gynecological Cancer	PO-238
<u>A. Qu</u> , J. Wang, P. Jiang, W. Jiang, H. Sun, X. Li, J. Dong (China)	
Ultrasound vs MRI CTV-HR in cervical BrachyT: US underestimate volume in patients with bad response	PO-239
<u>A.E. Villafranca Iturre</u> , A. Sola, N. Fuentemilla, S. Pellejero, P. Navarrete, M. Barrado, M. Rico, A. Martin, M. Rodriguez, L. Rosas (Spain)	
Clinical outcome of MRI-guided brachytherapy in cervical cancer: initial experience in Romania	PO-240
<u>A. Marinca</u> , I. Iftincai, E. Manea, A. Anghelache, A. Constantin, M. Oprisan, M. Oprea, I. Butuc, A. Rogojanu, A. Zara, E. Birleanu, D.A. Tanase, C. Tabrea, M.V. Marinca (Romania)	
Impact of Vaginal Reference Length on Organs at Risk doses in Carcinoma Cervix Brachytherapy	PO-241
<u>H.K. Bajwa</u> , R. Singareddy, K.R. Alluri, D. Shiva (India)	
HDR interstitial brachytherapy with radiosensitizer named as KORTUC for radiorefractory tumors	PO-242
<u>K. Yoshida</u> , T. Shimbo, N. Yoshikawa, T. Komori, H. Yoshioka, M. Nakata, A. Hori, C. Sato, Y. Uesugi, K. Nihei (Japan)	

Magnetic resonance imaging-guided for electronic brachytherapy in locally advanced cervical cancer.	PO-243
<u>A. Campos Bonel</u> , M. Cerrolaza Pascual, M. Gascon Ferrer, A. Méndez Villamon, A. Miranda Burgos, D. Villa Gazulla, V. Navarro Aznar, C. Garcia Aguilera, C. Escuin Troncho, R. Ibáñez Carreras (Spain)	
Multi-material 3D Printing in Brachytherapy -- Prototyping Teaching Tools	PO-244
<u>S. Campelo</u> , O. Craciunescu, E. Subashi, J. Chino (USA)	
Comparison of isodose surface volumes estimated by the TPS & TRAK in Cervical cancer brachytherapy	PO-245
<i>Abstract withdrawn</i>	
A Pilot Study of Quantitative Silicone Oxygen Sensors in HDR Cervical Cancer Brachytherapy	PO-246
<u>L. Lee</u> , G. Ekchian, J. Tokuda, R. Cormack, M. Cima (USA)	
PDR vs HDR brachytherapy (BT) in cervix carcinoma: dosimetric comparative study in 10 patients	PO-247
<u>A. Serre</u> , P. Pommier, F. Gassa (France)	

World Congress of Brachytherapy
Poster: Brachytherapy: Head and neck

Lip cancer treatment through high-rate brachytherapy	PO-249
<u>I. Alda Bravo</u> , A.C. Marina, F.A. Sandra, R.G. Virginia, D.M. Rafael, L.P. David, C.M. Eduardo, P. José Fermín (Spain)	
An Alpha-Emitting Radionuclide for Treating Locally Advanced Recurrent Skin and Head and Neck SCC	PO-250
<u>A. Popovtzer</u> (Israel)	
Pilot study of adjuvant brachytherapy to the primary and external therapy to the neck in Ca tongue	PO-251
<u>V. Anand</u> , K. Venkatesan, M. Lala, S. Deshpande, S. Naidu, R. Kabre, R. Harijani-Hinduja, P. Arulkar, K. Chauhan (India)	
Computed Tomography-Guided High-dose-rate brachytherapy in head and neck carcinoma	PO-252
<u>L. Xiang</u> , W. JingBo (China)	

World Congress of Brachytherapy
Poster: Brachytherapy: Physics

Real-time fluoroscopic verification of an HDR Ir-192 source position using a flat-panel detector	PO-253
<u>T. Nose</u> , K. Masui, T. Takenaka, H. Yamazaki, K. Nakata, Y. Otani, S. Kumita (Japan)	
Reconstruction method dependence of PET/CT dosimetry following transarterial radioembolization	PO-254
<u>M. McKee</u> , B. Thompson, T.M. Downing, B.E. Kouri, W.A. Dezarn (USA)	
125I Brachytherapy via a Trans-superior Vena Cava Approach for 4R Mediastinal Metastases	PO-255
<u>B. Liu</u> , L. Yuliang (China)	
Prostate HDR boost: urethra V110 constraints correspond to low adverse effects	PO-256
<u>I. Iftimia</u> , H. Hsu, P. Halvorsen (USA)	
Dwell positions of the source in Ring Applicator ("z-coordinate") in HDR brachytherapy commissioning	PO-257
<u>V. Stserbakov</u> , A. Tsizik, N. Saveljev (Estonia)	
Dosimetric Analysis of Combined Intracavitary and Interstitial Needles Placement for Cervical Cancer	PO-258
<u>J. Shiao</u> , T.J. Patton, D.E. Holt, T.P. Robin, C.M. Fisher (USA)	
Dosimetry of Intraocular Tumors with Small Apical Heights Using I-125 Plaques	PO-259
<u>M. Rezaee</u> , E. Huang, M. Morcos, H. Quon, A.P. Kiess, Z. Correa, H. Robert (USA)	
A treatment analysis tool for clinical, dosimetric and outcome data reported in the EMBRACE trial	PO-260
<u>S. Ecker</u> , C. Kirisits, Y. Seppenwoolde, K. Tanderup, A. De Leeuw, A. Sturdza, M. Schmid, G. Heilemann, R. Pötter, N. Nesvacil (Austria)	
BrachyClip with Iodine-125 seed	PO-261
<u>J. Dupere</u> , D. E Wazer, T. A DiPetrillo, J. J Munro III, D. C Medich (USA)	

Radiation protection preparedness using LASAIR in case of malevolent use of brachytherapy sources	PO-262
<u>T. Palmqvist</u> , H. Walter, G. Heinrich, I. Toma-Dasu (Sweden)	
Radiochromic film and optical fiber in vivo dosimetry evaluation for brachytherapy high dose rate.	PO-263
<u>M. Gautier</u> , A. Mana, J. Feuillade, L. Burgaud, D. Lam Cham Kee, M. Chand, J. Hannoun-Levi (France)	
Non-clinical Evaluation of BrachyVision Volumetric Evolutionary Gradient based Optimizer (VEGO)	PO-264
<u>R. Patel</u> , J. Roeske (USA)	
Healthy tissue constraints for catheter position optimization in HDR prostate brachytherapy planning	PO-265
<u>M.C. Van der Meer</u> , D. Van Dorth, P.A.N. Bosman, B.R. Pieters, Y. Niatsetski, T. Alderliesten, A. Bel (The Netherlands)	
Dosimetry evaluation for 3D printing template guided 125I seeds implantation in lung metastasis.	PO-266
<u>D. Liu</u> , W. Huang, X. Fan, J. Li, H. Wang, S. Yang (China)	
A study of brachytherapy isodose surfaces transition for assessment of quality of implant geometry	PO-267
<u>A. Christensen</u> , J.A. Cunha, <u>I. Hsu</u> (USA)	
Fast Radiation Dose Calculations for Brachytherapy Applications via Deep Learning	PO-268
<u>X. Mao</u> , J. Pineau, R. Keyes, S.A. Enger (Canada)	
Investigation of obstructions in ring applicators during pulsed dose rate cervix brachytherapy	PO-269
G. Menon, B. Long, E. Yip, R. Petit, Y. Niatsetski, J. Zimmer, K. Gadbois, E. Wiebe, J. Cuartero, F. Huang, D. Robinson, <u>B. Chow</u> (Canada)	
Robustness evaluation of interstitial liver brachytherapy using 4DCT	PO-270
<u>A.S. Duque</u> , R. Steffens, P. Freislederer, M. Reiner, F. Kamp, M. Seidensticker, F. Streitparth, F. Walter, K. Parodi, F. Verhaegen, G. Paiva Fonseca, J. Ricke, C. Belka, S. Corradini, G. Landry (Germany)	
Replacing TG-43U1 by TG-186 in liver brachytherapy has a dosimetric impact on treatment plans	PO-271
<u>A.S. Duque</u> , S. Corradini, F. Kamp, M. Seidensticker, F. Streitparth, F. Walter, K. Parodi, F. Verhaegen, J. Ricke, C. Belka, G. Landry, G. Paiva Fonseca (Germany)	

A multi-protocol validation study of automated bi-objective planning for HDR prostate brachytherapy	PO-272
<u>A. Bouter</u> , T. Alderliesten, B.R. Pieters, S. Buus, Y. Niatsetski, P.A.N. Bosman (The Netherlands)	
Impact of patient positioning on interstitial multicatheter HDR brachytherapy of the breast	PO-273
<u>N. Abu-Hossin</u> , K. Kallis, V. Strnad, R. Fietkau, C. Bert (Germany)	
Accuracy of in vivo dosimetry based source-tracking in HDR prostate brachytherapy	PO-274
<u>E. Jørgensen</u> , G. Kertzscher, K. Tanderup, J.G. Johansen (Denmark)	
Dosimetry of prostate brachytherapy with two dose levels and RM-US fusion of index lesion	PO-275
<u>J.C. Sanchez</u> , V. Gónzalez-Pérez, A. Montaner, A. Sanchez, J. Vilanova, B. Quiles, M. Peña, A. La Rosa, V. De los Dolores, C. Guardino, V. Crispín (Spain)	
Evaluation of Oncentra Brachy ACE® using Monte-Carlo simulations in the context of penile treatments	PO-276
<u>A. Carré</u> , I. Dumas, R. Sun, G. Klausner, S. Achkar, E. Deutsch, C. Chargari, C. Robert (France)	
An artificial neural network model for treatment plan verification in vaginal cuff HDR brachytherapy	PO-277
<u>C.N. Moleko</u> , <u>M. Carrara</u> , C. Tenconi, T. Giandini, A. Cerrotta, B. Pappalardi, F. Piccolo, C. Delle Curti, E. Pignoli (Italy)	
Development of Fast Methods for Patient Specific Microdosimetry of Brachytherapy Sources	PO-278
<u>J. Decunha</u> , F. Villegas-Navarro, M. Vallières, S. Camilleri-Broët, S. Abbasinejad Enger (Canada)	
Automatic verification of correct assembly and absolute source strength for COMS plaques	PO-279
<u>S. Lee</u> , G. Cohen, A. Rozenfeld, T. Brennen, M. Petasecca, S. Alnaghy, A. Damato (USA)	
A quantitative approach to pre-treatment verification of fractionated penile HDR mold brachytherapy	PO-280
<u>G. Cohen</u> , M. Kollmeier, P. Booth, S. Hellman, K. Episcopia, A. Damato (USA)	
Randomized comparison of SBRT and HDR brachytherapy for prostate cancer:analysis of dosimetric plans	PO-281
<u>S. Novikov</u> , J. Melnik, N. Ilin, R. Novikov, M. Gotovchikova, M. Girshovitch, S. Kanaev (Russian Federation)	

Autoradiography method for determination of actual source dwell positions in Elekta ring applicators	PO-282
<u>A. Tsizik</u> , N. Saveljev (Estonia)	
Utilisation of CCVT for estimation of number of catheters with HIPO in HDR-brachytherapy of prostate	PO-283
<u>I. Sachpazidis</u> , J. Mohom, D. Baltas (Germany)	
Inverse versus forward optimisation methods in brachytherapy of breast, cervix and prostate cancer	PO-284
<u>G. Fröhlich</u> , G. Geszti, J. Vízkeleti, P. Ágoston, C. Polgár, T. Major (Hungary)	
Dosimetric impact of reconstruction errors of an interstitial brachytherapy applicator Venezia™	PO-285
<u>F. Gassa</u> , M. Salima, T. Edwin (France)	
Is there a role of model-based dose calculation algorithms in interstitial breast brachytherapy?	PO-286
<u>T. Major</u> , G. Fröhlich, N. Mészáros, V. Smanykó, C. Polgár (Hungary)	
Do results improve when using an inverse planning multi-solution tool in HDR prostate brachytherapy?	PO-287
<u>N. Fuentemilla Uriو</u> , V. Raposo, A. Fernandez, R. Estrada, J. Escobar, S. Pellejero, L. Bragado, F. Mañeru, F. Caudepon, S. Miquelez, M. Barrado, P. Navarrete, A. Sola, E. Villafranca (Spain)	
Reconstruction of interstitial HDR brachytherapy needles based on MR data	PO-288
<u>V. Newton</u> , R. Wills, G. Lowe, W. McGuire, J. Moore-Taylor (United Kingdom)	
Ir-192 position measurement for pre-treatment QA using a fluorescent screen-based optical detector	PO-289
<u>W.Y.V. Lee</u> , K.K. Kwan, M.H.R. Lo, S.K. Cheung, H.F.V. Lee (Hong Kong (SAR) China)	
Primary standards and measurement methods for X-ray emitting electronic brachytherapy devices	PO-290
<u>T. Schneider</u> , R. Behrens, K. Tanderup, G. Kertzscher, V. Blideanu, C. Stien, J. Plagnard, J. Solc, V. Sochor, M. Pinto, T. Sander, A. Subiel, C. Gouldstone, L. De Prez, F. Verhaegen, B. Reniers (Germany)	
Commissioning of a Venezia applicator: discrepancies between expected and actual source positions	PO-291
<u>N. Fuentemilla Uriو</u> , A. Fernandez, R. Estrada, J. Escobar, S. Pellejero, F. Mañeru, L. Bragado, F. Caudepon, S. Miquelez, A. Rubio (Spain)	

Water equivalency of materials used for 3D printing in brachytherapy	PO-292
R. Wilks, <u>S. Crowe</u> (Australia)	
A planning study evaluating the Advanced Collapsed cone Engine for HDR skin brachytherapy	PO-293
<u>R. Stansbridge</u> , R. Caines, C. Lee (United Kingdom)	
An experimental verification of the Advanced Collapsed cone Engine for HDR skin brachytherapy	PO-294
<u>R. Stansbridge</u> , R. Caines, C. Lee (United Kingdom)	
In vivo dosimetry with radiochromic films in endometrial treatments with electronic brachytherapy	PO-295
<u>S. Lozares</u> , A. Gandía, J.A. Font, V. Alba, M. Hernández, S. Jiménez, D. Villa (Spain)	
Deep learning for automated applicator reconstruction in high-dose-rate prostate brachytherapy	PO-296
<u>L. Weishaupt</u> , H. Kamal Sayed, C.R. Choo, B. Stish, C. Deufel (USA)	
Developing and evaluating a deep neural network for applicator digitisation in brachytherapy	PO-297
<u>C. Andersén</u> , T. Rydén, P. Thunberg, J. Heydorn Lagerlöf (Sweden)	
In vivo dosimetry in temporary HDR prostate Brachytherapy	PO-298
<u>A. Pereira</u> , S. Pinto, J. Lencart (Portugal)	
RapidBrachyMCTPS 2.0: A Monte Carlo Based Treatment Planning System for Brachytherapy Applications.	PO-299
H. Glickman, M. Antaki, <u>S. Abbasi Nejad Enger</u> (Canada)	
Does removing rectal gas result in improved dose distributions for gynecological brachytherapy?	PO-300
<u>I. Vergalasova</u> , M. Sayan, J.N. Yue, L. Hathout (USA)	
Error detection in HDR brachytherapy with plan-specific optimization of in-vivo dosimetry parameters	PO-301
M. Collier, G. Cohen, D. Aramburu, <u>A. Damato</u> (USA)	
Differences between measured and certified RAKRs among Italian brachytherapy centers	PO-302
G. Montanari, E. De Ponti, M. Giacometti, L. Tesei, S. Comi, C. Frigerio, G. Sangalli, H.S. Mainardi, D. Zanni, M.G. Brambilla, G. Mazzotti, C. Di Venanzio, M. Piergentili, G. Rinaldin, C. Bianchi, F. Tanzi, B. Ghedi, <u>M. Carrara</u> (Italy)	

World Congress of Brachytherapy
Poster: Brachytherapy: Prostate

HDR Provides Better Proximal Seminal Vesicle Coverage: Dosimetric Comparison with LDR Brachytherapy	PO-303
<i>Abstract withdrawn</i>	
Catheter displacements and dosimetric impact in focal salvage high-dose-rate prostate brachytherapy.	PO-304
<u>M. Moerland</u> , M. Van Son, M. Peters, W. Eppinga, R. Schokker, J. Lagendijk, J. Van der Voort van Zyp (The Netherlands)	
Focal (subtotal) Idr brachytherapy for primary and recurrent prostate cancer – experiences 2013-2019	PO-305
<u>J. Zimmermann</u> , C. Moustakis (Germany)	
Transrectal ultrasound (TRUS) guided prostate brachytherapy: Advantages of relaxed probe position	PO-306
<u>E. Jaworski</u> , C. Evans, V. Narayana, B. Yao, L. Gharzai, M. Cousins, R. Dess, P. Hurley, P. McLaughlin (USA)	
Prostate radiotherapy rectal sparing: synergy with combo- brachy, gradient optimization, and SpaceOAR	PO-307
<u>M. Cousins</u> , E. Short, V. Narayana, R. Vokopola, E. Jaworski, R. Dess, P. Hurley, P. McLaughlin (USA)	
Impact of hydrogel SpaceOAR on rectal dosimetry and toxicity in low-dose-rate prostate brachytherapy	PO-308
<u>W.L. Ong</u> , M. Tacey, D. Bolton, A. Tan, Y. Chan, C.W. Cham, H. Ho, M. Guerrieri, F. Foroudi, D. Lim Joon, V. Khoo, K. McMillan, G. Koufogiannis, M. Liu, M. Chao (Australia)	
Pre-Treatment HDR Catheter Position Verification for Prostate BT: A Dosimetric Evaluation	PO-309
<u>S. Graves</u> , S. Collins, R. Smith, V. Panettieri, S. Miller, B. Matheson, J. Millar (Australia)	
The tortoise and the hare: A nursing view on two workflows for HDR brachytherapy for prostate cancer	PO-310
<u>M. Roach</u> , D. Todor, R. Sharpe, A. Urdaneta (USA)	
Outcomes following salvage brachytherapy for prostate cancer: a comparison between different eras	PO-311
<u>G. Alban</u> , B. Mahal, J. Adleman, A. D'Amico, P. Nguyen, P. Orio, M. King (Brazil)	

A knowledge based treatment planning approach for Low-Dose-Rate Brachytherapy	PO-312
<u>C. Guthier</u> , P.F. Orio, I. Buzurovic, R.A. Cormack (USA)	
Automatic treatment planning for focal low-dose-rate prostate brachytherapy	PO-313
<u>S. Mahdavi</u> , M. Peacock, I. Spadiner (Canada)	
Using PSA kinetics to predict 5yr biochemical failure in intermediate-risk prostate cancer patients.	PO-314
<u>T. McMullan</u> , B. Nailon, D. McLaren, A. Law, W. Keough, T. Ronaldson, J. Mitchell, T. Berger (United Kingdom)	
Toxicity Of Salvage Brachytherapy For Post Radiation Failure Or Primary Brachytherapy With Seeds	PO-315
M. Quivrin, F. Coutault-Deslandes, E. Martin, I. Bessieres, D. Chambade, L. Cormier, <u>G. Crehange</u> (France)	
Registration accuracy of an integrated MR -TRUS navigation system for prostate HDR brachytherapy	PO-316
R. Shams, C. Menard, D. Lopera, D. Bélieau-Nadeau, G. Delouya, K. Boudam, J. Carrier, <u>S. Kadoury</u> (Canada)	
Interstitial HDR brachytherapy as monotherapy or a boost for high risk prostate cancer.	PO-317
<u>S. Novikov</u> , S. Kanaev, R. Novikov, N. Ilin, M. Gotovchikova, M. Girshovich (Russian Federation)	
Real Time Intraoperative Planning Reduces Toxicity In Ldr Brachytherapy Boost In Prostate Cancer	PO-318
<u>M. Barrado Los Arcos</u> , E. Villafranca, A. Sola, P.A. Navarrete, N. Fuentemilla, S. Pellejero, A. Galbete, A. Martín, M. Rodríguez, E. Martínez (Spain)	
Do all MRI detected T3a patients have the same outcomes after HDR-Brachytherapy and EBRT?	PO-319
<u>A. Gomez-Iturriaga</u> , D. Buchser, I. San Miguel, A. Urresola, A. Gil, A. Ezquerro, A. Gonzalez, F. Suarez, M. Esther, L. Martinez-Indart, A. Frias, O. Del Hoyo, J. Cacicedo, F. Casquero (Spain)	
Developing a High-Volume, High-Efficiency CT-Based High Dose Rate Prostate Brachytherapy Workflow	PO-320
<u>B. Barney</u> , R. Manigold, I. Gordon, M. Cornia, R. Hecox (USA)	
Risk factors for urethral stricture following HDR brachytherapy boost for prostate cancer	PO-321
<u>N. Groom</u> , G. Lowe, P. Hoskin (United Kingdom)	

Dose-escalation with High-Dose-Rate Brachytherapy boost in high-risk prostate cancer	PO-322
<u>S. Flamarique</u> , E. Villafranca, A. Martín, M. Rodriguez, M. Barrado, M. Campo, A. Sola, P. Navarrete, L. Rosas, S. Pellejero, N. Fuentemilla, A. Galbete, E. Martinez (Spain)	
Protocol-based image-guided salvage brachytherapy as re-irradiation for recurrent prostate cancer	PO-323
<u>V. Strnad</u> , N. Schönle, M. Lotter, S. Kreppner, R. Fietkau (Germany)	
High-Dose Rate (HDR) Brachytherapy For Very-High Risk (Vhr) Prostate Cancer	PO-324
<u>A.E. Villafranca Iturre</u> , I. Martinez Montesinos, A. Sola, P. Navarrete, S. Pellejero, N. Fuentemilla, M. Barrado, M. Rico, A. Martin, M. Illas, M. Rodriguez, E. Martinez (Spain)	
Results of combined radiotherapy in patients with high-risk prostate cancer	PO-325
<u>A. Potapova</u> , I. Gladilina, A. Petrovsky, V. Matveev, V. Sholokhov, V. Chernyaev, B. Bukharkin, R. Valiev (Russian Federation)	
Treatment outcomes and toxicity in patients treated with LDR brachytherapy, retrospective study	PO-326
<u>P. Lukacko</u> , B. Obsitnik, A. Molnarova, J. Grezdo, D. Fuggerova, K. Polakova (Slovakia)	
Technical Evaluation of 3D printed Disposable Seed Loader for LDR Cs-131 Prostate Brachytherapy	PO-327
<u>M. Khosravi</u> , T.C. Harris, E.H. Neubauer Sugar, D.A. O'Farrell, I.M. Buzurovic (USA)	
TRUS guided one step HDR brachytherapy boost in localized carcinoma of Prostate-long term results	PO-328
<u>V. Anand</u> , S. Deshpande, S. Naidu, K. Venkatesan, V. Joshi, R. Kabre, R. Harijani-Hinduja, P. Arulkar, K. Chauhan (India)	
MR guided single fraction Prostate HDR Brachy: a Phase 2 study of focal radiation therapy (ProFocAL)	PO-329
<u>T. Brunner</u> , F. Fischbach, D. Schindeler, M. Schostak, M. Pech, K. Fischbach, P. Hass (Germany)	
Early clinical outcomes in localized prostate cancer treated with monotherapy 20 Gy brachytherapy	PO-330
L. Larrea, E. Lopez-Munoz, <u>V. Gonzalez</u> , P. Antonini, M.A. Berenguer, M.C. Banos, J. Bea, J.D. Lago (Spain)	

MRI-Guided Robotic Prostate Biopsy and Brachytherapy: Update from the EU-funded CoBra Project	PO-331
<u>S. Wilby</u> , A. Palmer, W. Polak, A. Labib, D. Jones, S. Firouzy, D. Hodgson, Y. Nagar, P. Wiskerke, J. Van Den Dobbelsteen, M. De Vries, S.S. Dhaliwal, R. Merzouki (United Kingdom)	
Clinical outcomes of radiation therapy for high-risk prostate cancer	PO-332
<u>G. Yuliya</u> , K. Makarova, V. Biryukov, A. Obukhov (Russian Federation)	
HDR Brachytherapy Monotherapy for low and favorable intermediate risk prostate cancer.Early analysis	PO-333
<u>S. Rodríguez Villalba</u> , P. Monasor Denia, M.J. Pérez-Calatayud, J. Richart Sancho, J. Pérez-Calatayud, M. Santos Ortega (Spain)	
Real time dynamic LDR Brachytherapy boost to external beam radiotherapy in prostate cancer	PO-334
<u>S. FORNER</u> , E. Xing, S. Ravindra, A. DSouza, F. Leach, T. Guerrero Urbano, V. Mullassery, O. Elhage, R. Popert, S. Morris (United Kingdom)	
Comparison of early radiation toxicity between fractionation schedules of prostate HDR brachytherapy	PO-335
<u>T. Krzysztofiak</u> , P. Wojcieszek, S. Kellas-Sleczka, P. Lelek, M. Stankiewicz (Poland)	
US-guided EM tracked system compared to OncentraProstate for HDR brachytherapy: a first in-men study	PO-336
<u>M. Lavallée</u> , A. Cantin, L. Martine, F. William, B. Luc, V. Eric (Canada)	
8-year outcome after MR-guided HDR BT boost for intermediate- and high-risk prostate cancer	PO-337
<u>F. Lakosi</u> , G. Antal, A. Farkas, M. Csima, A. Gulyban, G. Toller (Hungary)	
HDR Prostate Brachytherapy – Is 20 needles too many?	PO-338
<u>J. Wilson</u> , A. Lydon, C. Trewin (United Kingdom)	
Subdomains of erectile and urinary function after ultrafocal HDR-brachytherapy for prostate cancer	PO-339
<u>M. Peters</u> , M. Van Son, M. Moerland, J. Lagendijk, T. Shah, H. Ahmed, J. Van der Voort van Zijp (The Netherlands)	

Comparison of two different Low Dose Rate (LDR) Brachytherapy techniques – a retrospective analysis.	PO-340
<u>C. Villalon Arias</u> , M. Bidmead, H. Eyles, V. Khoo, K. Roberts, Y. Suh (United Kingdom)	
HDR brachytherapy as a boost in unfavorable prostate cancer: toxicity and early clinical outcomes	PO-341
<u>J. Zafra Martin</u> , I. Ribeiro, J.I. Rodriguez-Melcon, J.L. Perez-Molina, B. Pinar-Sedeño, I. Gonzalez-Vein, E. Dominguez, M. Lloret (Spain)	
HDR brachytherapy monotherapy with 2 x 13.5 Gy for localized prostate cancer: short term follow up	PO-342
<u>M. Maenhout</u> , K. De Vries, P. Jansen, L. Luthart, I. Kolkman-Deurloo, M. Christianen (The Netherlands)	
HDR boost in high-risk prostate cancer: twice vs single fractions, are there any differences?	PO-343
<u>S. Rodríguez Villalba</u> , P. Denia Monasor, M.J. Pérez-Calatayud, J. Richart Sancho, J. Pérez -Calatayud, M. Santos Ortega (Spain)	
HDR-BT vs exclusive EBRT in local gross relapse of prostate carcinoma after radical prostatectomy	PO-344
<u>D. Büchsler</u> , A. Gomez-Iturriaga, F. Casquero, A. Gonzalez, F. Suarez, E. Mayrata, J.M. Espinosa, F. Perez, J. Cacicedo, L. Martinez-Indart, P. Bilbao (Spain)	
Predictors of biochemical failure after salvage brachytherapy for radiorecurrent prostate cancer	PO-345
<u>A. Chakravorty</u> , C. Gerhart, K.A. Nguyen, E. Chang, P. Venkat, A. Lee, J. Demanes, A. Chang (USA)	
Preliminary results of MR-guided Focal Brachytherapy Boost to SABR for Localized Prostate Cancer	PO-346
<u>C.H. Fong</u> , P. Bettoli, A.Z. Liu, T. Craig, A. Bayley, A. Rink, R.A. Weersink, S. Raman, J. Helou, P. Warde, P. Chung, A. Berlin (Canada)	
The insider view on differences between CT and US prostate HDR: A tumorlet perspective	PO-347
<u>D. Todor</u> , A. Urdaneta, A. Ricco (USA)	
High dose rate brachytherapy with 2 fractions of 13.5 Gy as monotherapy in localized prostate cancer	PO-348
<u>S. Kariya</u> , S. Ashida, I. Yamasaki, K. Inoue, T. Yamagami (Japan)	

Performance of an integrated MRI/PET-TRUS system with EM tracking for tumor-targeted prostate HDR	PO-349
<u>C. Menard</u> , D. Orlando Grajales Lopera, R. Shams, M. Barkati, G. Delouya, D. Bélieau-Nadeau, B. Nicholas, K. Boudam, D. Juneau, S. Kadoury, J. Carrier (Canada)	
Long-term outcomes of prostate cancer patients treated with low dose rate Brachytherapy.	PO-350
<u>T. McMullan</u> , B. Nailon, D. McLaren, W. Keough, A. Law, J. Mitchell, T. Ronaldson, T. Berger (United Kingdom)	
Pre rectal spacing with, Blood Patch in HDR Prostate Brachytherapy, Can We improve our dosimetry?	PO-351
D. Martinez Perez, <u>R. Del Castillo</u> , G. Sarria Bardales, L. Pinillos Ashton, F.A. Usuga Torres, R. Chumbimuni Contreras, L.A. Maya, I. Veliz, B. Carrion Peñafiel, C. Flores, L. Chirinos, A. Salgado (Peru)	
Antibiotic Prophylaxis for Prostate Brachytherapy : Interim Results of a Randomized Controlled Study	PO-352
<u>T. Derashodian</u> , N. Lussier, E. De Castro Hillmann, M. Bertrand, G. Wakil, J. Martineau, M. Jolicoeur (Canada)	
Prostate cancer HDR brachytherapy monotherapy : urinary acute and late toxicity predictives factors	PO-353
<u>M. Jolicoeur</u> , T. Derashodian, T.V. Nguyen, E. De Castro Hillmann, R. Heliou, G. Wakil, M. Nachabe, E. Antebi, M. Mondat (Canada)	
Early tolerance of HDR brachytherapy boost plus SBRT in high and intermediate risk prostate cancer	PO-354
<u>A. GOEL</u> , D.J. Gorovets, M.F. Hopkins, T.H. Beckham, M.A. Kollmeier, S.M. McBride, D. Shasha, M.J. Zelefsky (USA)	
MR-assisted salvage HDR prostate brachytherapy with intra-prostatic boost: a prospective study	PO-355
<u>H. Chung</u> , A. Loblaw, C. Tseng, J. Murgic, D. Laura, A. Ravi, M. Davidson, M. Wronski, M. Haider, G. Morton (Canada)	

World Congress of Brachytherapy
Poster: Brachytherapy: Anorectal

The impact of intraluminal brachytherapy boost in anorectal cancer radiotherapy	PO-356
<u>O. Ivanov</u> , D. Ivanov, N. Prvulović (Serbia)	

Applicator visualization using ultrashort echo time MRI for HDR endorectal brachytherapy	PO-357
<u>R. Van den Ende</u> , E. Ercan, R. Keesman, E.M. Kerkhof, C.A.M. Marijnen, U.A. Van der Heide (The Netherlands)	

World Congress of Brachytherapy
Poster: Brachytherapy: Miscellaneous

Dosimetry, efficacy and safety of I-125 seed implantation for retroperitoneal lymphatic metastases	PO-358
<u>Y. CHEN</u> , Y. Jiang, Z. Ji, X. Fei, Z. Pu, H. Sun, L. Runhong, G. Fuxing, L. Xuemin, J. Wang (China)	
HDR brachytherapy as a component of induction chemoradiotherapy for operable esophageal cancer	PO-359
<u>E. Tiuriaeva</u> (Russian Federation)	
Trend of HDR brachytherapy in Japan	PO-360
<u>J. Itami</u> , H. Ikushima, T. Dokiya, T. Nishimura (Japan)	
Iodine-125 Eye Plaque Brachytherapy in the Management of Patients with Large Choroidal Melanomas	PO-361
<u>J. Sanders</u> , D. Muller, S. Dutta, Y. Shilkrot, S. Scarboro, J. Larner (USA)	
Impact of corrected dosimetry in ocular brachytherapy	PO-362
<u>F.J. Celada Alvarez</u> , N. Carrasco, J. Chimeno, M.J. Pérez Calatayud, R. Martinez Costa, J. Gimeno, L. Farga, M. Rodriguez Pla, E. Marttin, O. Prato, V. Carmona, F. Lliso, J.C. Ruiz, A. Conde, J. Pérez Calatayud (Spain)	
The paediatric brachytherapy ramp-up at our institute	PO-363
<u>R. Davila Fajardo</u> , H. Dehnad, J.H.M. Merks, L.E. Smeele, P. Saeed, R. Knops, R. Schokker, M. Moerland, P. Kroon (The Netherlands)	
CircRNA Expression Profile in Peripheral Blood from liver cancer Patients with 125I Brachytherapy	PO-364
<u>Y. Zhang</u> , M. Luo, S. Peng, H. He, M. Ke, F. Zhang (China)	
An efficacy analysis of image-guided adaptive HDR brachytherapy for malignant obstructive jaundice	PO-365
<u>L. Sun</u> , R. Jiang, J. Zhao, H. Huang (China)	

Interstitial Cs-131 brachytherapy for refractory brain lesions.	PO-366
<u>L. Hammoudeh</u> , I. Buzurovic, D. O'Farrell, T. Harris, E.C. Dee, T. Johnson, K. Wu, M. Mooney, L. Bi, P. Devlin (USA)	
HDR interstitial spine brachytherapy using an intraoperative CT-guided surgical navigation system	PO-367
<u>S. Park</u> , S. Tenn, L. Macyszyn, P. Venkat, A. Lee, A. Chang (USA)	
Intracardial brachytherapy for salvage of right ventricular metastasis from NSCLC combined with SBRT	PO-368
<u>T. Brunner</u> , P. Hass, M. Walke, I. Dittrich, A. Schmeisser, J. Achenbach, K. Fischbach, R. Braun-Dullaeus (Germany)	
Evaluation of early clinical response of CT-guided HDR interstitial brachytherapy in HCC	PO-369
<u>F. Walter</u> , F. Fuchs, D. Konnerth, J. Well, L. Nierer, G. Landry, M. Seidensticker, F. Streitparth, J. Ricke, C. Belka, S. Corradini (Germany)	
CT-guided high-dose interstitial brachytherapy vs. SBRT for hepatocellular carcinoma	PO-370
<u>F. Walter</u> , A. Duque, H. Weingandt, J. Well, R. Shpani, L. Nierer, G. Landry, M. Seidensticker, F. Streitparth, J. Ricke, C. Belka, S. Corradini (Germany)	
Practicability of adapting a US simulation-based brachytherapy course for an international audience	PO-371
<u>S. Damast</u> , L. Singer, E. Fields, S. Felder (USA)	
Percutaneous Iodine-125 Implantation for the Treatment of Recurrent Fibrosarcoma After Surgery	PO-372
<u>W. Wang</u> , Y. Li (China)	
Effectiveness and safety of CT-guided 125I seed implantation for advanced non-small-cell lung cancer	PO-373
<u>W. Wang</u> , Y. Li (China)	
CT-guided Iodine-125 Seeds Implantation for Mediastinal Metastasis from Lung Squamous Cell Cancer	PO-374
<u>B. Liu</u> , Y. Li (China)	
High-dose-rate brachytherapy in the management of lung cancer: a single-institution experience	PO-375
<u>A. ARSENIEV</u> , S. Kanaev, S. Novikov, K. Gagua, F. Antipov, A. Barchuk (Russian Federation)	
An analysis of Ir-192 HDR brachytherapy combined with EBRT in treatment of TACC	PO-376
<u>W. Guo</u> , T. Hu, Y.C. Sun (China)	

Biological effects of 125I seeds and 60Co radiation on lung adenocarcinoma cells	PO-377
<u>Q. Shan</u> (China)	
Implementation of intensive educational program for quality care of the HDR brachytherapy patient	PO-378
<u>K. Kafka-Peterson</u> (USA)	
Dosimeter Evaluation for Measurement of Radial Dose Distributions for Electronic Brachytherapy	PO-379
<u>A. Walter, L. DeWerd</u> (USA)	
Volumetric Dosimetry for Eye Plaque Brachytherapy Using 3D Treatment Planning Software	PO-380
<u>M. Rezaee, E. Huang, M. Morcos, H. Quon, A.P. Kiess, Z. Correa, R. Hobbs</u> (USA)	
perioperative radiation with/without high dose rate brachytherapy for high-risk soft tissue sarcoma	PO-381
<u>J. Assif, W. Ennis, R. Chaudhari, B. Kim, S. Rice, A. Shapiro, T. Damron, S. Tanny, A. Banashkevich, J. Bogart</u> (USA)	
Intraoperative High-dose-rate Brachytherapy: Current Status	PO-382
<u>D.N. Sharma, R. Kulshrestha</u> (India)	
Clinical value of robot positioning system in CT-guided interventional operation for thoracic tumors	PO-383
<u>C. Liu, D. Li</u> (China)	
Efficacy of 3D Printing Template Assisted 125I seed Implantation as treatment of Soft Tissue Sarcoma	PO-384
<u>X. LI, J. Wang, Y. Jiang, Z. Ji, R. Peng, F. Guo, Y. Chen, H. Sun, J. Fan, W. Li</u> (China)	
Assessment of Role of intraluminal brachytherapy as palliative treatment in esophageal malignancies	PO-385
<u>V. Pareek, R. Bhalavat, M. Chandra, L. Nellore, K. George, D. Borade</u> (India)	
Brachytherapy for paediatric pelvic tumours	PO-386
<u>J. Chard, J. Karpelowsky, E. Flower, G. Busuttil, J. Bucci, V. Ahern</u> (Australia)	
Percutaneous ct-guided permanent iodine-125 implantation as therapy for pulmonary metastasis	PO-387
<u>X. Huo</u> (China)	
Implantation of CT-guided 125I in Combination with Chemotherapy for Treatment of Stage III NSCLC	PO-388
<u>X. Huo</u> (China)	


Interstitial brachytherapy as bridging prior to liver transplantation in hepatocellular carcinoma	PO-389
<u>S. Corradini</u> , F. Walter, F. Fuchs, D. Konnerth, M. Guba, J. Well, L. Nierer, G. Landry, M. Seidensticker, F. Streitparth, J. Ricke, C. Belka (Germany)	
A Dosimetric Analysis of Dose De-Escalation Using BED Modeling for Eye Plaque Brachytherapy	PO-390
<u>N.V. Patel</u> , M.T. Studenski, A. Markoe, J.W. Harbour, S.E. Samuels (USA)	
Post-assembly detector-based quality assurance for brachytherapy eye plaques	PO-391
<u>S. Moehle</u> , I. Spadinger, M.J.P. Chamberland (Canada)	
CHALLENGES OF BRACHYTHERAPY IN NIGERIA; OUR JOURNEY SO FAR	PO-392
<u>M. Ali-Gombe</u> , Y.S. Sadiq, F.M. Bala, D.B. Adamu, M.I. Mustapha, A.U. El-Nafaty (Nigeria)	
Dose to Organs at Risk after High Dose Rate Brachytherapy for Esophageal Cancer Patients	PO-393
<u>S. Darvish-Molla</u> , E. Timotin, J. Skoczny, T. Farrell, R. Sur (Canada)	
Episcleral Brachytherapy for Uveal Melanoma - Reference Center experience	PO-394
<u>B. Moura Fernandes</u> , D. Correia, T. Teixeira, J. Casalta-Lopes, P. César Simões, C. Fonseca, J. Veríssimo, M. Da Luz Cachulo, R. Proença, M. Borrego (Portugal)	
HDR brachytherapy for primary tumors of murine B16-F10 melanoma.	PO-395
<u>T. Cichon</u> , R. Smolarczyk, M. Jarosz-Biej, A. Hadyk, J. Czapla, S. Matuszcak, E. Pilny, Z. Urbaś, A.J. Chyrek, P. Wojcieszek (Poland)	

World Congress of Brachytherapy

Poster: Brachytherap: Skin

High Dose Rate Brachytherapy for skin cancer: results and toxicities for 70 cases in Nancy, France	PO-396
<u>S. Renard-Oldrini</u> , J. Salleron, J. Py, E. Meknaci, M. Cuenin, I. Buchheit, V. Marchesi, S. Huger, C. Charra-Brunaud, D. Peiffert (France)	

Clinical outcomes of high dose rate brachytherapy for non melanoma cutaneous malignancies	PO-397
<u>P. Venkat</u> , C. Zarate, Y. Yang, S. Park, A. Chang, M.A. Hagio, A. Lee (USA)	
The use of mono brachytherapy in treatment of soft tissue sarcomas	PO-398
V. Suslava, P. Demeshko, J. Bogdaev, E. Tskhovrebov, A. Suslova, <u>D. Kazlouski</u> (Belarus)	
Superficial HDRBT in NMSC: Results and toxicity For Differents Superficial Applicators.	PO-399
<u>S. Rodríguez Villalba</u> , P. Monasor Denia, M.J. Pérez -Calatayud, J. Richart Sancho, J. Pérez-Calatayud, M. Santos Ortega (Spain)	
HDR Brachytherapy with the Valencia applicator for Non Melanoma Skin Cancer: The Leeds Experience	PO-400
<u>S. Ramasamy</u> , P. Bownes, I. Boon, S. Namini, C. Richardson (United Kingdom)	
HDR 192-Ir surface brachytherapy in the treatment of basal cell skin cancer in elderly patients	PO-401
<u>M. Stankiewicz</u> , P. Wojcieszek (Poland)	
HDR brachytherapy for treatment of primary cutaneous lymphoma at complex sites and curved surfaces	PO-402
<u>V.R. Sim</u> , I. Defrancesco, F. Child, M. Wain, S. Whittaker, K. Freeman, E. Jones, S. Aldridge, S. Morris (United Kingdom)	

The background of the poster is a large, solid orange triangle pointing upwards. To its right is a dark blue parallelogram. A white circle is located at the intersection of the orange triangle's hypotenuse and the bottom edge of the blue parallelogram. There are also several thin, horizontal black lines on the left side.

#WCB2020

Follow us on    

www.estro.org